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cAMP and cGMP are important second messengers in the cardiovascular system. 
Previously, it has been demonstrated that the cardiac ryanodine receptor (RyR2) forms a 
microdomain associated with key contributors of cAMP signaling such as PKA, PDE4D3 and 
various phosphatases. Its calcium release channel function is highly regulated by cAMP and 
its effector kinase PKA; hyperphosphorylation of the channel occurs in heart failure and 
causes arrhythmias. A transgenic mouse model was generated with cardiomyocyte specific 
expression of the FRET-based cAMP indicator Epac1-camps-JNC. Epac1-camps-JNC is a 
targeted version of the cytosolic cAMP sensor Epac1-camps by its fusion with junctin protein, 
which forms a complex with calcium release units to permit locally restricted real time 
visualization of cAMP dynamics in vicinity of the RyR2. Stimulation of the β1-adrenergic 
receptor strongly increased cAMP levels, while the β2-induced signals were hardly detectable 
in this microdomain. Furthermore, it was found that PDE3 and PDE4 are the major 
contributors to local cAMP catabolism. cAMP dynamics recorded with the localized Epac1-
camps-JNC were compared with cAMP signaling in the bulk cytosol using cardiomyocytes 
isolated from Epac1-camps mice. Yet there were no significant differences detectable in 
cAMP signaling between the cytosol and the RyR2 compartment.     
cGMP is another important second messenger which is considered cardioprotective, and the 
agents that raise cGMP are under investigation in clinical trials for hypertension and heart 
failure. However, little is known about the spatio-temporal dynamics of cGMP in adult 
cardiomyocytes. Therefore, a new transgenic mouse model with cardiomyocyte-specific 
expression of the FRET-based biosensor red cGES-DE5 was generated to allow real time 
visualization of cGMP dynamics with nanomolar sensitivity in living adult cardiomyocytes. In 
these cells, basal cGMP levels were amounted to ~10 nmol/L. It was found that they are 
generated by NO-GC activity and β3-adrenergic receptors are involved in the regulation of 
unstimulated cGMP levels. A strong increase upon stimulation of GC-B with CNP was 
observed, while ANP which stimulates GC-A evoked only minor effects. In contrast, NO 
donors such as SNAP failed to raise cGMP via activation of NO-GC, most likely due to low 
expression levels of NO-GC in adult cardiomyocytes. Surprisingly, cGMP degradation was 
mainly mediated by PDE3 hydrolytic activity, while PDE1, 2 and 5 seemed to be not involved 
in cGMP turnover. In a model of compensated cardiac hypertrophy, PDE3 remained the 
major cGMP-PDE and PDE5 activity was upregulated. PDE3 is well known as a major 
cAMP-PDE and regulator of myocyte contractility. However, it is also established that PDE3 
is inhibited by cGMP, since it degrades both cyclic nucleotides with high affinity but has a 10-
fold higher catalytic activity for cGMP compared to cAMP. To elucidate the role of PDE3 is 
 Abstract  
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cyclic nucleotide interplay, cardiomyocytes isolated from transgenic mice expressing the 
cytosolic cAMP sensor Epac1-camps were subjected to FRET-based measurements of 
cAMP. After β-adrenergic stimulation, application of CNP increased cAMP levels due to 
cGMP-mediated PDE3 inhibition, thus confirming the major role of PDE3 in cGMP/cAMP 
crosstalk. 
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1   Introduction 
1.1   Cyclic nucleotide signaling and its relevance for physiology  
3´,5´-cyclic adenosine monophosphate (cAMP) and 3´,5´-cyclic guanosine monophosphate 
(cGMP) are ubiquitous second messengers that are involved in the regulation of numerous 
physiological functions. Since its discovery in 1957,1 it has been demonstrated that cAMP 
regulates secretion of insulin in pancreatic β-cells,2 immune function,3, 4 5 learning and 
memory,6, 7 gene expression8, 9 and division of cells.10 In the heart, cAMP mainly mediates 
excitatory effects of β-adrenergic receptors on cardiac function.11 Formation of cAMP is 
modulated via G-protein coupled receptors (GPCRs), which induce cAMP synthesis through 
stimulatory G-proteins (Gs) or inhibit cAMP generation via inhibitory G-proteins (Gi). These G-
proteins affect adenylyl cyclases (ACs), which catalyzes the conversion of adenosine 
triphosphate to cAMP. As cAMP effector proteins, cyclic nucleotide gated ion channels 
(CNGs),12 exchange protein directly activated by cAMP (Epac),13 and protein kinase A 
(PKA)14 were identified.  
cGMP regulates visual and olfactory transduction,15 renal function by inhibition of aldosterone 
and renin secretion,16-18 bone growth,19 gastrointestinal motility,20, 21 bladder function,22 as 
well as penile erection,23 metabolism24, 25 and brown fat cell differentiation.26 In the central 
nervous system, cGMP is considered to control a wide range of functions, such as axon 
guidance27 and synaptic plasticity.18, 28 cGMP plays an important role in the cardiovascular 
system, where signaling by cGMP is involved in the regulation of cardiac contractility,29 
pathological remodeling,30 platelet function,31 vascular smooth muscle tone and hence blood 
pressure.32  Formation of cGMP is catalyzed by guanylyl cyclases (GCs), in particular by the 
soluble guanylyl cyclase (NO-GC), which is mainly located in the cytosol and signals through 
nitric oxide (NO). Membrane-associated guanylyl cyclases (particulate guanylyl cyclases) are 
the receptors for the hormones atrial (ANP), B-type (BNP), and C-type natriuretic peptides 
(CNP), and the intestinal peptide guanylin. ANP and BNP are agonists for GC-A, CNP binds 
to GC-B, and guanylin was demonstrated to affect GC-C activity.25 However, the family of 
particulate guanylyl cyclases consists of seven isoforms (GC-A through GC-G), while ligands 
were identified only for the first four isoenzymes.33 Three major cGMP binding partners have 
been identified, namely several phosphodiesterases (PDEs), cyclic nucleotide gated ion 
channels (CNGs) and cGMP-dependent kinases (cGKs). It was demonstrated that cGMP 
binds to cyclic nucleotide binding domains present in various PDEs (so called GAF domains, 
found in such PDEs as PDE2, PDE5, PDE10, and PDE11) to regulate PDE catalytic 




PDE2 hydrolytic activity and thus cAMP catabolism by an allosteric process.35 This 
mechanism allows interplay of cAMP and cGMP signaling. In addition, cGMP activates 
CNGs, a mechanism most prominent in the visual and olfactory systems.36 Last but not least, 
cGMP mediates phosphorylation of substrates via cGMP-dependent kinases (cGKs).25             
1.2   cAMP signaling in cardiomyocytes 
1.2.1   Cardiac excitation-contraction coupling and its regulation by PKA   
In cardiomyocytes, the movement of Ca2+ between various subcellular compartments and 
between cell cytosol and extracellular space facilitates contraction and relaxation of the 
heart. Myocyte contraction involves electric and contractile components (excitation-
contraction coupling).37 Initially, an electric signal (action potential) depolarizes the surface 
membrane of a cardiomyocyte (sarcolemma) and activates voltage-gated Ca2+ channels (L-
type Ca2+ channels, LTCCs) to cause an inward Ca2+ current (ICa). LTCCs are located in 
invaginations of the sarcolemma (T-tubules) in close proximity to the Ca2+ release channel 
(cardiac ryanodine receptor isoform, RyR2) to permit the formation of a local Ca2+ signaling 
complex (couplon).38 A single couplon contains 10-25 LTCCs and 100-200 RyRs,39 to allow 
the calcium-induced calcium release (CICR) from the sarcoplasmic reticulum (SR), which 
serves as Ca2+ storage organelle in cardiomyocytes. However, activation of a single couplon 
does not affect contractility; it is necessary that all couplons are activated at the same time 
by an action potential to induce a robust Ca2+ transient that activates the contraction 
machinery.39 During myocyte contraction (systole), cytosolic Ca2+ levels are elevated due to 
Ca2+ influx via LTCCs and Ca2+ release from the SR through RyRs. To permit relaxation 
(diastole), Ca2+ is restored into the SR by the sarcoplasmic/endoplasmic reticulum Ca2+ 
ATPase 2a pump (SERCA2a), which is negatively regulated by phospholamban (PLB) and 
extruded by the Na+/Ca2+ exchanger (NCX).39  A small amount of the Ca2+ is extruded by 
sarcolemmal Ca2+-ATPase and mitochondrial Ca2+ uniporter.38, 40 The amplitude and velocity 
of Ca2+ cycling is ultimately translated into cardiac performance and regulated by 
catecholamines, which stimulate β-adrenergic receptors (β-AR) and mediate the “fight-or-
flight” mechanism.11 In particular, stimulation of the β1 subtype results in strong cAMP 
formation and activation of PKA, which phosphorylates proteins involved in Ca2+ cycling. 
Phosphorylation of the LTCC,41 PLB,42 RyR2,43 and troponin I (TnI)44 occurs and results in 
enhanced Ica, increased Ca
2+ reuptake mediated by SERCA2a, increased Ca2+ release from 
the SR, and altered Ca2+ sensitivity of the myofilaments to increase cardiac performance and 
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complex. (A) Ca
2+
 transients regulate myocyte contraction and relaxation. Cytosolic Ca
2+
 is increased 
by Ca
2+
 influx through the LTCC (L-type Ca
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 channel) and Ca
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 cycling itself is modulated by catecholamines (the synthetic catecholamine 
isoproterenol is shown) to mediate the “fight-or-flight” mechanism mainly via activation of β1-
adrenergic receptors (β1-AR). PKA phosphorylates the LTCC, RyR, PLB and TroponinI (TnI). 
Phosphorylation of TnI affects Ca
2+
 sensitivity of the myofilaments (myoficaments are not shown in the 
cartoon). (B) The RyR2 is a tetrameric ion channel and consist of 4 identical subunits arranged around 
a pore region. Each subunit contains a short C-terminal transmembrane segment, associated with 
junctin, triadin and calsequestrin (CSQ), and a cytosolic foot-shaped domain that serves as a scaffold 
to complex regulatory proteins and enzymes. Calstabin2, protein kinase A (PKA), Ca
2+
/calmodulin-
dependent kinase II (CaMKII), PDE4D3, phosphatases 1 and 2a (PP1 and PP2A), calmodulin (CaM), 
and sorcin are associated with the N-terminal domain. PKA and CaMKII phosphorylation sites are 
shown at serine 2808 and 2814, respectively. The schematic illustration of the RyR2 signaling 
complex was taken from Lehnart et al.
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1.2.2   Local cAMP signaling at the RyR2  
In cardiomyocytes, the concept of cAMP microdomains is highly relevant since cAMP is not 
uniformly distributed within the cell but is rather organized in subcellular compartments. 
Initially, it was found that agonists of β-adrenergic and prostaglandin receptors both caused 
an increase in cAMP and PKA activity in the cytosolic fraction of homogenates from rabbit 
myocytes. In contrast, only β-AR agonists affected cAMP and PKA activity in the particulate 
fraction, while stimulation of prostaglandin receptors could not, although both agonists led to 
comparable cAMP amounts produced in whole cell lysates.46 Since then, a wealth of 
information has provided proof for the existence of subcellular cAMP compartments or 
microdomains (there are also few studies on cGMP microdomains), where cyclic nucleotide 
signaling occurs in a spatially and temporally highly defined manner.47-49 Key components 




kinases and receptors. The RyR2 has been associated with various regulatory proteins and 
assumed to be highly regulated by local cAMP levels.43, 50, 51 The concept of cAMP 
compartmentation will be illustrated by dissection of the RyR2 signaling complex (Fig. 1B).  
The cardiac RyR2 is a homotetrameric ion channel and consists of 4 identical subunits of 
~565 kDa each (and ~2 mega Da size for the entire channel), which are arranged around a 
pore region to gate Ca2+ ions.37, 45 Each subunit consists of a relatively short C-terminal 
transmembrane segment and a huge cytosolic foot-shaped domain, which serves as a 
scaffold for a complex of regulatory proteins and enzymes.37, 52 The C-terminus in the SR 
lumen has been associated with triadin and junction, which anchor the Ca2+ binding protein 
calsequestrin (CSQ) to the RyR2 to form a quaternary complex, termed Ca2+ release unit.37, 
53, 54 It was demonstrated that calstabin2,55 PKA,43 Ca2+/calmodulin-dependent kinas II 
(CaMKII),56 phosphodiesterase 4D3 (PDE4D3),50 phosphatases 1 and 2a (PP1 and PP2A), 
calmodulin protein (CaM), and sorcin are associated with the N-terminal domain.37 
Calstabin2 is a 12.6 kDa polypeptide that binds to the RyR2 and stabilizes the closed state of 
the channel. One calstabin2 molecule can bind per RyR2 subunit.45 The PKA is associated to 
the RyR2 macro complex via muscle A kinase-anchoring protein (mAKAP).37 The cytosolic 
RyR2 domain provides leucine/isoleucine zipper motifs to facilitate binding of mAKAP. PKA 
phosphorylates the RyR2 at serine position 2808 (Ser2809 in the human sequence), 
whereas another phosphorylation site at serine 2030 is discussed.57 In addition, PDE4D350 
and phosphatases58 are targeted to the RyR2 signaling complex and locally regulate cAMP 
levels and PKA activity, respectively. CaMKII-mediated phosphorylation of the RyR2 at 
serine 2814 has been demonstrated.56 It is worth mentioning that channel phosphorylation 
regulates the RyR2, without directly opening or closing the channel, but modifies the 
sensitivity of the channel to its physiological ligand Ca2+. Finally, calomdulin and the 22 kDa 
protein sorcin have been found to inhibit RyR2-dependent Ca2+ release59 and to be involved 
in channel closure after Ca2+ release.37, 60, 61 
1.2.3   PKA-mediated Ca2+ leak hypothesis 
Over the past 15 years, diastolic Ca2+ leak through dysfunctional RyRs has been recognized 
as an important mechanism in heart failure. Initially, Marks and colleagues postulated that 
chronic hyperphosphorylation of serine 2808 by PKA causes depletion of calstabin2 from the 
RyR2, which results in increased sensitivity to Ca2+ and open probability of the receptor 
during diastole.43 Thus, PKA-dependent hyperphosphorylation causes leaky RyRs, which 
decrease SR Ca2+ content and cause arrhythmias during heart failure. Indeed, 
catecholaminergic overstimulation is a hallmark of heart failure,11, 62 but it is also a dogma 




failure.63, 64 A possible explanation is that remodeling causes local depletion of PDE4D3 and 
phosphatases from the RyR2 macrocomplex50, leading to increased phosphorylation of the 
RyR2, while global cAMP levels are decreased. However, this hypothesis is highly 
controversial, and hyperphosphorylation of Serine 2808, which causes calstabin2 
dissociation from the RyR2, has been challenged by several other studies.65-67  
1.3   cGMP signaling in cardiomyocytes 
1.3.1   cGMP formation by guanylyl cyclases 
cGMP formation is catalyzed by guanylyl cyclases, located in the cytosol or associated with 
the cellular membranes. The major role of gaseous NO and its receptor NO-GC is highly 
appreciated in the vascular system, but it became obvious that the NO/NO-GC/cGMP 
signaling pathway also directly affects cardiomyocyte function. In such a setting, NO derived 
from cardiac endothelial cells, diffuses into surrounding cardiomyocytes or NO generation 
occurs within cardiomyocytes.68 Although, NO donor effects on heart function have been 
controversial, there is a growing body of evidence that suggests positive effects on 
contractility after stimulation with low amounts of NO,69-71 while higher levels exert a negative 
inotropic response.72-74 The postulated mechanism for the negative inotropic response 
includes cGKI-dependent phosphorylation of TnI, causing a decreased responsiveness of the 
myofilaments to Ca2+.75 It was recently demonstrated that stimulation of β3-adrenoceptors 
causes a negative inotropic response in the human or mouse ventricle that is mediated via 
an NO-dependent mechanism.76, 77 Finally, NO donor-derived cGMP attenuates β-adrenergic 
responses75 and signaling of cGMP is thought to induce a protective brake for the heart after 
catecholaminergic stimulation.  
In general, NO is released from NO-generating drugs (NO-donors) or is endogenously 
synthetized by oxidation of the amino acid L-arginine to L-citrulline and NO, which is 
catalyzed by NO synthase activity (NOS).78, 79 The family of NOS enzymes consist of 3 
isoforms, including neuronal NOS (nNOS or NOS1), inducible NOS (iNOS or NOS2) and 
endothelial NOS (eNOS, NOS3), with all of them expressed in cardiac myocytes.80 eNOS 
and nNOS are activated by Ca2+/calmodulin complex, while iNOS activation is mediated by 
cytokines.78, 81  NO stimulates NO-GC catalytic activity a several hundred-fold, causing an 
increase in cGMP concentrations. NO-GC is a heterodimeric enzyme that consists of one α 
and one β subunit, the α1 β1 heterodimer is the most highly abundant isoform and 
physiologically relevant.82 The heterodimer contains a prosthetic heme group with a ferrous 
iron, located at the N-terminus of the β1 subunit. NO coordinates to the heme moiety and 




activity is complex, and it has been shown that NO binds to the heme to form a six-
coordinate complex (His105-FeII-NO), which is not stable and turns into a five-coordinate 
complex (FeII-NO).83 Breakage of the bond between histidine 105 of the β subunit and 
ferrous iron of the heme cofactor leads to a conformational change in the catalytic domain of 
the protein and causes an increase in cGMP formation.79, 84 A low-activity complex has been 
identified at low NO concentrations and a high-activity complex at elevated NO.79, 85 In the 
presence of Mg2+ and guanosine triphosphate (GTP) or the reaction products (Mg2+, cGMP, 
pyrophosphate PPi), the high-activity complex is preferentially formed,
86 while the presence 
of adenosine triphosphate (ATP) benefits the formation of the low-activity complex.87 
However, functional NO-GC activity and effective cGMP synthesis is strongly dependent on 
nitroso-redox balance.88 Oxidative stress is associated with cardiovascular disease and 
causes the formation of reactive oxygen species (ROS). NO reacts with superoxide radical 
(O2¯) to form peroxynitrite (ONOO¯), which has been shown to decrease NO-GC sensitivity.
89, 
90 Hence, ROS interferes with NO-GC/cGMP signaling via scavenging of NO and causes 
insensitive NO-GC.91 In addition, other mechanisms explaining depressed NO-GC/cGMP 
signaling have been proposed.84, 91-93 It was demonstrated that oxidized NO-GC loses its 
heme group and is susceptible to degradation. Stasch et al. introduced the compound BAY 
58-2667 (Cinaciguat), which is capable of activating oxidized NO-GC in a heme-independent 
manner.91  
The natriuretic peptide hormones ANP, BNP and CNP induce cGMP generation through 
binding to its membrane-associated guanylyl cyclase receptors that catalyze cGMP 
formation.94 These enzymes form the family of particulate guanylyl cyclases, which comprise 
a common topology33 that includes an extracellular ligand-binding domain, a short 
hydrophobic membrane-spanning region, and an intracellular region. The intracellular region 
contains a kinase-homology domain (KHD), a hinge region, and a C-terminal cyclase 
homology domain (CHD).95 The role of the KHD is incompletely understood, the hinge region 
is involved in the formation of dimers and higher oligomers, which are required for an active 
enzyme. Finally, the CHD catalyzes the conversion of GTP into cGMP.95  
ANP is synthesized and stored as a pre-hormone, mainly in atrial myocytes and released as 
mature hormone upon atrial wall stretch.96 In the circulation, ANP is strongly involved in the 
regulation of arterial blood pressure and blood volume in an endocrine manner through 
stimulation of GC-A activity in various tissues.95 The main effects include relaxation in 
specific vascular beds,97 counteraction of the renin-angiotensin-aldosterone- and 
sympathetic system and stimulation of renal diuresis.95 98 Mice with absent ANP or lacking 
the GC-A receptor showed salt-resistant hypertension,32, 99 while transgenic mice with 




a decrease in arterial blood pressure.100, 101 However, it became clear that ANP also directly 
influences cardiac myocytes, which is relevant in cardiovascular disease such as heart 
failure, where ANP and BNP levels are highly elevated.95 BNP is mainly synthesized in 
ventricular myocytes,96 circulating BNP plasma levels are significantly lower than those of 
ANP,102 and BNP shows lower affinity for GC-A receptor compared with ANP.103 Despite the 
fact that both peptides share the same receptor, mice with targeted disruption of BNP lacked 
hypertensive and hypertrophic phenotypes but revealed severe cardiac fibrosis.104 Given the 
fact that cardiac fibroblasts express high levels of GC-B,105 BNP is most likely induced to 
counterbalance fibrosis during heart failure and is less involved in the regulation of blood 
pressure homeostasis.   
CNP is mainly synthesized in the vascular endothelium106 and exerts effects through its 
receptor GC-B. In contrast to ANP, CNP has only little effect on the blood pressure107 and is 
found only in trace amounts in the blood. Hence its endocrine function might be minor, and 
more local paracrine effects have been postulated for CNP. GC-B is abundant in the 
vasculature, bone, brain, at high levels in cardiac fibroblasts,95 108 and is also expressed in 
cardiomyocytes.109-111 Disruption of the CNP encoding gene caused severe dwarfism in 
mice,19 while mice lacking the natriuretic peptide clearance receptor (NPRC), showed bone 
overgrowth due to decreased CNP degradation.112 CNP synthesis was reported in the hearts 
of patients with chronic heart failure,113 and GC-B-mediated cGMP formation was detected in 
myocardium from heart failure patients.114 Finally, CNP has been shown to affect heart 
contractility, whereas ANP does not.29, 78, 115, 116  
1.3.2   cGMP degradation by phosphodiesterases 
Degradation of cGMP levels is mediated via PDE hydrolytic activity. PDEs are grouped into 
11 families, expression and functional roles in cGMP signaling has been described for PDE1, 









Isoform Substrate Specificity 
Km 
cGMP          cAMP 
(µmol/L) 
Vmax (purified) 
cGMP          cAMP 
(µmol/min/mg) 
Reference 
PDE1A cAMP<cGMP 2.6-3.5 72.7-124 50-300 70-450 119-122 
PDE1B cAMP<cGMP 1.2-5.9 10-24 30 10 123, 124 
PDE1C cAMP=cGMP 0.6-2.2 0.3-1.1 - - 125, 126 
PDE2A cAMP=cGMP 10 30 123 120 127, 128 
PDE3A cAMP>cGMP 0.02-0.15 0.18 0.34 3.0-6 129, 130 
PDE3B cAMP>cGMP 0.28 0.38 2.0 8.5 131 
PDE5A cAMP<cGMP 2.9-6.2 290 1.3 1.0 132-134 
Table 1. Biochemical characterization of PDE enzyme kinetic properties; Km is the Michaelis-
Menten constant, Vmax describes the maxiumum enzyme activity, - no information available; modified 
from Bender et al.
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The PDE1 family (often referred as the “Ca2+/calmodulin-dependent PDE”) constitutes 3 
isoforms (PDE1A, PDE1B and PDE1C), with all of them showing dual substrate specificity. 
PDE1A and PDE1B preferentially degrade cGMP over cAMP, while PDE1C hydrolyzes both 
cyclic nucleotides with equal affinity.135 PDE1 is unique due to the fact that it can be activated 
by Ca2+/calmodulin (Ca2+/CaM) complex and thereby decreases cyclic nucleotide levels.80 
The PDE1 enzymes contain an inhibitory domain which, when interacting with the catalytic 
domain, causes less active enzyme. Binding of Ca2+/CaM releases the catalytic domain and 
relieves the inhibition of cyclic nucleotide hydrolysis.121 In addition, its catalytic activity is 
negatively influenced by phosphorylation through PKA and CaMKII, leading to decreased 
recruiting of Ca2+/CaM and hence slower cyclic nucleotide degradation.121, 136 PDE1C is 
highly expressed in human cardiomyocytes,137 while PDE1A is the predominant isoform in 
rodent myocytes.138 Despite the fact that PDE1 is strongly involved in cyclic nucleotide 
breakdown in human myocardium,137, 139 little is known about its physiological effects in the 
heart, mainly due to the lack of highly specific PDE1 inhibitors.78  
The PDE2 family (often referred as the “cGMP-stimulated PDE”) is encoded by a single gene 
and consists of 3 isoforms (PDE2A1-3), which differ in their subcellular localization. PDE2A2 
and PDE2A3 are membrane associated, whereas PDE2A1 lacks an N-terminal localization 
motif and is cytosolic.117 PDE2 can hydrolize cAMP and cGMP with high catalytic activity 
(high Vmax), while it shows low affinity (low Km) for both cyclic nucleotides.
118 Highly 
remarkable is the fact that cGMP can activate PDE2 catalytic activity, which is mediated 
through binding of cGMP to regulatory GAF-B domains.34 Therefore, PDE2 is often referred 
to as the cGMP- stimulated PDE. Its contribution to total cGMP hydrolysis is considered to be 




after β-adrenergic activation. Thus, cAMP levels induced by catecholamines can be 
counterbalanced by PDE2 cAMP catabolism, which is strongly regulated by cGMP. Initially, it 
was reported that cGMP does not affect LTCC-gated Ca2+ currents in cells from frog ventricle 
at basal state, but decreases these after β-adrenergic stimulation, and this effect is mediated 
by stimulation of PDE2.140 Mongillo et al. showed that catecholamines increase cAMP 
through stimulation of β1/2-adrenergic receptors, in parallel cGMP is synthetized due to 
activation of the β3-AR, and this specific pool of cGMP activates PDE2 hydrolytic activity and 
shapes the concomitant cAMP signal.35 Furthermore, PDE2 has been associated with the 
plasma membrane in neonatal rat cardiomyocytes35, and it was demonstrated that PDE2 is a 
key regulator of cyclic nucleotide compartmentation in neonatal and adult rat 
cardiomyocytes. Castro et al. showed that PDE2 regulates cGMP levels, produced by GC-
A.49, 141 
The PDE3 family contains PDE3A1/2/3 and PDE3B isoforms. PDE3B is associated with the 
particulate fraction, and PDE3A is found in the soluble and particulate fractions. Both 
isoenzymes are regulated by PKA phosphorylation to increase its catalytic activity.118 PDE3 
is a dual substrate enzyme and shows high affinity for both cyclic nucleotides but hydrolyzes 
cAMP with a 10-fold higher catalytic activity compared to cGMP. Thus cGMP can act as a 
competitive inhibitor to cAMP catabolism and PDE3 is often referred as “the cGMP-inhibited 
PDE”.118 It has been established that PDE3 is a major contributor to total cAMP breakdown in 
cardiomyocytes, and is strongly involved in the regulation of contractility.142 Indeed, 
peripheral vasodilating actions and positive inotropic effects made inhibition of PDE3 a 
promising target for heart failure drugs. However, despite positive actions on hemodynamics 
and heart function, long-term treatment with inhibitors of PDE3 caused increased mortality in 
heart failure patients mainly due to arrhythmias and sudden cardiac death.143 So far, 
milrinone in intravenous dosage form is approved for short-term treatment of acute 
cardiogenic shock. Importantly, downregulation of PDE3 was reported in a mouse model of 
pressure overload and in heart failure patients, which was associated with increased 
cardiomyocyte apoptosis. As a possible mechanism, an upregulation of the proapoptotic 
transcriptional repressor ICER (inducible cAMP early repressor) due to PDE3 downregulation 
was postulated.144 Furthermore, a cardioprotective role of PDE3A was observed after 
ischemia/reperfusion injury in mice.145 
PDE5 (also referred as the “cGMP-specific PDE”) is probably the most well characterized 
cGMP-PDE, and its selective inhibitors (sildenafil, tadalafil, vardenafil) are approved for the 
treatment of erectile dysfunction and pulmonary hypertension. PDE5A is highly abundant in 
the lung, corpus cavernosum, platelets and vascular smooth muscle cells.117 In the heart 




hypertrophy and heart failure.30 The PDE5 family consists of 3 isoforms (PDE5A1-3) and 
hydrolyzes exclusively cGMP, with high affinity and selectivity. PDE5 hydrolytic activity is 
tightly modified by its substrate cGMP, which acts as an activator of enzyme catalytic activity. 
Association of cGMP to its specific binding domains (GAF-A domain) results in a ~10-fold 
increase in the catalytic activity of PDE5.118, 147 At high cGMP, cGKI phosphorylates the 
PDE5 to further raise catalytic activity and cGMP affinity of cGMP to the allosteric binding 
site (GAF-A domain).117 There is good evidence that PDE5 is an important mediator in cGMP 
compartmentation. Takimoto and colleagues showed that PDE5 activity is tightly associated 
with NOS3, and this specific coupling of cGMP generation and degradation is required to 
affect contractility. Inhibition of PDE5 in mice had minimal impact on basal heart function. 
However, after β-adrenergic stimulation, sildenafil markedly blunted inotropic response. This 
effect was strongly dependent on NOS3 activity, since sildenafil failed to attenuate 
contractility in mice with deleted NOS3. The mechanism included cGKI-dependent 
phosphorylation of TnI, to counterbalance contractility. Finally, it was demonstrated that the 
majority of PDE5 enzymes are localized to the Z-bands of the sarcomere, in close proximity 
to NOS3. NOS3 KO mice and treatment with a NOS inhibitor caused a diffuse PDE5 
expression pattern. Notably, inhibition of the redistributed PDE5 failed to suppress 
catecholamine-induced contractility.148 Castro et al. showed that NO-GC-induced cGMP 
pools are regulated by PDE5 hydrolytic activity in adult rat cardiomyocytes in vitro, while 
cGMP generated by GC-A activity were controlled by PDE2, further supporting the major role 
of PDE5 in compartmentalized signaling of cGMP.49     
1.3.3.   cGMP-dependent kinase 
cGMP activates its effector kinase cGK, which mediates phosphorylation of proteins (see Fig. 
2). Most prominent are phosphorylation of TnI and PLB, which are strongly involved in the 
regulation of myocyte contraction and relaxation (see Fig. 1A).149, 150 The cGK belongs to the 
family of serine/threonine kinases, and cGKI is the predominant isoform in the cardiovascular 
system. The architecture of cGKs includes an N-terminal domain, a regulatory domain 
(cGMP binding domain) and a C-terminal catalytic domain. The N-terminus is encoded by 2 
exons that are translated into cGKIα and cGKIβ splice variants, whith the cGKIα the 
dominant isoform expressed in cardiomyocytes.18 However, the N-terminal domain is 
involved in the formation of dimers (cGKIs are homodimers) and subcellular localization. The 
regulatory domain contains two in-tandem cGMP binding sites (A+B). Binding of cGMP 
induces a conformational change that results in a more elongated structure of the kinase, a 
feature that has been exploited for the generation of several cGMP biosensors. The catalytic 






Figure 2. cGMP dynamics in cardiomyocytes. Guanylyl cyclases (GCs) catalyze the formation of 
cGMP. Natriuretic peptides ANP, BNP activate GC-A; GC-B is the receptor for CNP. NO binds to NO-
GC, the β3-adrenergic receptor (β3-AR) is associated with eNOS (NOS) which catalyzes the 
conversion of L-arginine to NO. cGMP activates its effector kinase cGKI  which phosphorylates 
phospholamban (PLB), troponin I (TnI) and PDE5 (more targets of cGKI have been identified such as 
VASP, but are not shown in the cartoon). cGMP synthesis is counterbalanced by phosphodiesterase 
(PDE) hydrolytic activity. Finally, cGMP modifies cAMP levels via PDE2 and PDE3 to facilitate a 
crosstalk between both cyclic nucleotides; cAMP is generated by adenylyl cyclase (AC) activity.  
1.3.4   cGMP signaling in cardiac hypertrophy 
Cardiac hypertrophy is a mechanism of the heart to adapt to wall stress. Increased 
hemodynamic overload or decreased contractile force after myocardial infarction causes wall 
stress and elevated oxygen consumption, which is counterbalanced by cardiac growth and 
results in compensative thickening of the walls to sustain cardiac performance. However, the 
initially adaptive process can become maladaptive and ultimately leads to cardiac disease. 
The so-called fetal gene program is induced which leads to increased protein generation, 
changes in the organization of the sarcomere and enhanced cardiomyocyte size.151 On the 
molecular level, various signaling and transcription pathways are activated during 
hypertrophy.30 For instance, stimulation of angiotensin II, endothelin 1 and α-adrenergic 
receptors, which are coupled to Gq/11-proteins causes cardiac hypertrophy.
152 These 
pathways stimulate a remodeling process that induces disturbed Ca2+ cycling and 




arrhythmias. However, it is widely appreciated that signaling of cGMP inhibits hypertrophy, 
and thereby protects the heart from pathological myocyte remodeling.  
Initially, Calderone et al. found that ANP and NO donor attenuate norepinephrine-induced 
hypertrophy in cultured neonatal rat cardiomyocytes and fibroblasts, and that the ANP and 
NO effects on hypertrophic growth were mimicked by the cGMP analogue 8-bromo-cGMP.153 
Following these observations, a growing body of evidence suggests that cGMP formation 
after natriuretic peptide and NO stimulation, or after inhibition of its degradation, blunts 
pathological hypertrophy. Recently, β3-adrenoceptors, which are well known to regulate 
metabolism,154 gained great attention in the cardiovascular field and were proposed as 
potential targets to counterbalance hypertrophy and heart failure.155 This was based on the 
remarkable finding, that stimulation of β3-adrenoceptors causes a negative inotropic 
response76 and on the observation that this receptor is upregulated in human heart failure.156 
Furthermore, receptor activation requires high amounts of catecholamines (which are a 
hallmark of heart failure), and the β3-adrenoceptor is resistant to downregulation.
157 These 
characteristics are in clear contrast to those of the β1-AR, which is considered to induce a 
short-term positive effect on contractile force and heart beating frequency, while an overload 
of catecholamines is associated with receptor downregulation and detrimental effects on the 
long-term goal.11 Very recently, it was demonstrated that overexpression of the β3-AR 
attenuates catecholamine- and angiotensin II-mediated hypertrophy via NOS mechanism.158    
Global GC-A knock-out mice develop a hypertensive phenotype, which is associated with 
cardiac hypertrophy.159 Therefore, transgenic mice with cardiomyocyte-restricted deletion of 
GC-A were developed to elucidate anti-hypertrophic effects of ANP independent of blood 
pressure. These mice showed mild cardiac hypertrophy at baseline and inflated hypertrophic 
growth reaction after transverse aortic constriction160 and treatment with angiotensin II.161 In 
line with these observations, transgenic mice expressing a constitutively active GC-A mutant 
had increased cGMP levels within cardiomocytes and were protected against isoproterenol 
treatment and aortic banding.162 Antifibrotic and, more recently antihypertrophic 
characteristics have also been attributed to CNP, since in vitro data in cultured 
cardiomyocytes showed that CNP locally counter-regulated hypertrophy in adult rat 
cardiomyocytes.111 These observations were confirmed by in vivo studies using a myocardial 
infarction model in CNP-overexpressing mice163 and in rats with CNP infusion via osmotic 
mini pumps.164 Frantz et al. reported that deletion of cGKI in cardiomyocytes causes dilated 
cardiomyopathy after transverse aortic constriction and angiotensin II treatment. A depressed 
Ca2+ cycling was observed in the cGKI knock-out mice, mainly due to reduced CNP-




attenuates remodeling and pathological transformation into heart failure by maintaining 
myocyte Ca2+ handling and contractility during hypertrophy.165    
It has been shown that expression and cGMP catabolism of PDE1138 and PDE5166-168 are 
increased in human heart failure. Thus, it is widely accepted that inhibition of cGMP 
degradation to elevate cGMP levels is an attractive strategy to antagonize pathological 
hypertrophy and remodeling. Takimoto et al. demonstrated in a landmark paper that the 
PDE5 inhibitor sildenafil prevents cardiac hypertrophy after aortic banding in vivo. Sildenafil 
was even able to reverse pre-established mild hypertrophy.30 Cardioprotective effects of 
PDE5 inhibition were also reported in rodent models of doxorubicin cardiotoxicity169, 170 and 
ischemic injury.171-174 Still, the relevance of cardioprotective sildenafil effects for human heart 
is controversial, since the main cGMP turnover in human myocardium is attributed to PDE1 
and PDE3, and some sildenafil effect might be due to its low selectivity and concomitant 
inhibition of PDE1.175 Recently, the results from the RELAX trial revealed that in heart failure 
patients with preserved ejection fraction, sildenafil treatment showed no significant benefits 
versus placebo.176 However, ongoing clinical trials will further elucidate the usefulness of 
PDE5 inhibition using available oral drugs to treat heart failure. In this context, it is important 
to mention that the role of PDE1 was further studied, and it has been shown that PDE1A 
expression is strongly upregulated in various rodent models of cardiac hypertrophy. Likewise, 
the selective PDE1 inhibition attenuated cardiac hypertrophy in vitro and in vivo.138  
1.4   Methods for the visualization of cAMP and cGMP dynamics   
1.4.1   Challenges in the detection of cyclic nucleotide fluctuations 
Classical measurements of cGMP levels use biochemical techniques such as 
radioimmunoassays, enzyme-linked immunosorbent assays, and indirect detection of cyclic 
nucleotides using western blot analysis of substrate phosphorylation by effector kinases.177, 
178 These techniques require cell and tissue lysis and therefore lack information on the 
subcellular localization of cyclic nucleotide signaling events. In addition, total cyclic 
nucleotide amounts are detected despite physiologically relevant unbound cyclic nucleotides. 
Finally, it is worth mentioning that preincubation with IBMX is required in most cases to block 
cGMP degradation and enhance cGMP amounts to a detectable level during biochemical 
assays. This is highly relevant for cardiomyocytes, which produce low amounts of cGMP. It is 
also important to consider that signaling of cAMP and cGMP follows fast kinetics, and cyclic 
nucleotide fluctuations can occur rapidly and are transient.179-181 Excessive re-probing is 
necessary to gain insights into the temporal dynamics using classical biochemical assays 




(for instance cGMP amount 1, 2, 5 min after stimulation). To resolve those issues, a number 
of optical and non-optical techniques which allow visualization of spatiotemporal cAMP or 
cGMP dynamics in living cells have been described in recent years.  
1.4.2    Principle of fluorescence resonance energy transfer 
In the past ten years, the Förster/Fluorescence Resonance Energy Transfer (FRET) 
technique has gained great popularity in the study of biochemical events and protein-protein 
interactions in living cells (see Fig. 3). 
 
Figure 3. The FRET technique is applied to track cellular events. If donor (CFP) and acceptor 
fluorescent protein (YFP) come into close proximity, FRET occurs. FRET allows visualization of 
dynamic protein-protein interactions and conformational changes within a single protein; cyan 
fluorescent protein (CFP), yellow fluorescent protein (YFP). Figure from Zhang et al.
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FRET describes a non-radiative energy transfer between two fluorophores. The energy flows 
from an excited donor fluorescent protein to a nearby acceptor fluorophore through dipol-
dipol interactions which results in decreased (quenched) donor- and increased acceptor 
emission intensity. The occurrence of FRET strongly depends on three conditions. Namely, 
donor and acceptor have to be in closed proximity to each other, a beneficial orientation of 
the dipoles is essential, and donor emission spectrum and acceptor excitation spectrum need 
to overlap.183 In detail, the efficiency of the energy transfer strongly depends on the distance 
between the donor and acceptor molecules and varies as the inverse of the sixth power of 
the distance,183 as described by the Förster equation:  
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 is the distance between donor and acceptor fluorescent protein, where 50 % energy 
transfer occurs, this value can be calculated for each specific pair of fluorescent proteins. 
Highly notable is the fact that the FRET efficiency falls off with the sixth power, which 
indicates that FRET happens only within a highly defined distance, and thus FRET can be 




	 is specific for each FRET pair of fluorescent proteins and is calculated for aqueous 
solutions as follows: 
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 is the orientation angle variable and describes the angle between the two dipoles of the 
fluorophores. FRET efficiency strongly depends on the alignment of the fluorophores to each 
other. Parallel orientated dipoles of the fluorophores show higher FRET efficiencies 
compared with a perpendicular orientation. Values from 0 to 4 are theoretically possible, but 
in general, the value is fixed and close to 2/3.  is the donor quantum yield,  ! the maximal 
acceptor extinction coefficient, both values are constants. J " is the spectral overlap 
integral, which describes the region between the normalized donor emission spectrum &" 
and the acceptor excitation spectrum !": 
J "  '&" ∙ !" ∙ "()" 
In theory, for an optimal FRET pair, one has to choose a donor with high quantum yield, an 
acceptor with a strong extinction coefficient, and the donor emission and acceptor excitation 
spectra have to overlap (Fig. 4).185  
 
 
Figure 4. Overlap of CFP emission spectrum and YFP excitation spectrum. The CFP emission 
spectrum (cyan line) overlaps with the YFP absorption spectrum (yellow line) to allow FRET. The grey 









1.4.3   Biosensors for the visualization of cAMP dynamics 
Over the past 20 years, a large number of genetically encoded biosensors have been 
developed to allow visualization of cAMP dynamics in living cells. The great majority of cAMP 
indicators are based on the principle of FRET and contain a conformationally sensitive 
domain (cAMP binding domain) sandwiched between two fluorescent proteins to allow 
FRET. In most cases, cyan and yellow fluorescent proteins are selected as a FRET pair, but 
also other variants of green fluorescent protein (GFP) have been used. Biosensors based on 
PKA,142, 186, 187 cyclic nucleotide gated ion channels188 and Epac189-191 have been developed. 
These biosensors are introduced into living cells using conventional transfection techniques 
or viral gene transfer (which is necessary for cardiomyocytes).48 The probes were extensively 
used and largely improved the understanding of cAMP signaling and its compartmentation in 
cardiomyocytes. Highly notable is a transgenic mouse model with ubiquitous expression of 
the cytosolic cAMP indicator Epac1-camps.192 This cAMP indicator molecule contains a 
cAMP binding domain derived from Epac1 sandwiched between CFP and YFP as a FRET 
pair (Fig. 5).  
 
Figure 5. Principle of the Epac1-cAMP-sensor (Epac1-camps). The Epac1-camps is based on a 
single cAMP binding domain (CNBD) from Epac1 flanked by cyan and yellow fluorescent proteins. At 
low cAMP levels, donor (CFP) and acceptor (YFP) are in close proximity and FRET occurs.  Binding of 
cAMP to the CNBD induces a conformational change and a concomitant decrease in FRET. Excitation 
of CFP is at 436 nm, CFP and YFP emission are collected at 480 and 535 nm, respectively. The figure 
is from Nikolaev and Lohse.
193
   
1.4.4   Biosensors for the visualization of cGMP dynamics 
In contrast to extensive studies on cAMP dynamics using biosensors for cAMP, far less is 
known about cGMP, especially in cardiomyocytes. In the following, major cGMP biosensors 
and some of novel findings obtained using them in the cardiovascular system are briefly 

































































GFP/RFP 0.04 >100 >1000 198 
Table 2. Comparison of various fluorescent cGMP biosensors, EC50 and selectivity values are in 
vitro data using recombinant protein. For simplicity, ECFP, EYFP, T-Sapphire and Dimer2 are termed 
as CFP, YFP, GFP and RFP, respectively. Table has been modified from
196, 199
.      
Recently, the development of non-FRET-based fluorescent cGMP indicators, termed FlincGs 
(fluorescent indicators of cGMP) has gained great attention.194 These biosensors have a 
single circularly permuted enhanced GFP (cpEGFP) N-terminally fused to a regulatory 
domain fragment from cGKI. Association of cGMP induces a conformation change that 
causes an increase in fluorescence intensity of cpEGFP. Initially, two constructs, with 
regulatory domains from cGKIα and cGKIβ were created and termed α-, β-FlincG. These 
constructs showed strong increases in fluorescence intensities upon stimulation of 
recombinant proteins with cGMP, but the signals were strongly reduced after sensor 
expression in vascular smooth muscle cells (1.2-fold intensity change). However, a truncated 
version of α-FlincG has an absent N-terminal domain fragment, which mediates the formation 
of dimers. Thus, δFlincG did not interact with endogenous kinases, leading to a robust 
change in intensity (3.5-fold increase), even when expressed in primary cells, which makes 
the δFlincG superior to the other variants. The δFlincG showed high sensitivity, selectivity for 
cGMP over cAMP and rapid kinetics (see Table 2). The combination of live cell imaging with 
confocal microscopy was able to unravel spatio-temporal dynamics of cGMP. It was shown 
that in vascular smooth muscle cells, GC-A induced a cGMP pool that was located at the 
plasma membrane, while NO-GC evoked global elevations in cGMP. The spatial confined 
ANP signal could be transformed into a cytosolic one by inhibition of PDE5. Finally, it should 




wavelength (510 nm), whereas FRET-based biosensors necessitate collecting emission light 
at two wavelengths using a more sophisticated detection system.194  
Nevertheless, most of the cGMP indicators are based on the principle of FRET and contain a 
cGMP-binding domain that is sandwiched between two fluorescent proteins. Two types of 
cGMP binding domains are known, those found in cGK and cGMP regulated ion channels 
and cGMP binding domains from PDEs termed GAF domains. Interestingly, the cGMP 
binding domains are universally grouped in tandem pairs.180 The first engineered cGMP 
indicators contained partially truncated cGKI sandwiched between CFP and YFP. The sensor 
backbone, derived from cGKI contained almost the entire cGKI molecule including the two 
cGMP binding domains (A and B) and the catalytic domain, with only the N-terminal 
dimerization domain being deleted. In particular, Sato et al described an increase in 
fluorescence energy transfer upon stimulation in HEK 293 cells using CGY-Del1 probe,195 
while biosensors termed Cygnets, showed a decrease in FRET upon CNP stimulations in 
lung fibroblasts.197 Cygnet 2.1, which had the inactivated catalytic domain (threonin 516 was 
mutated to alanin) and YFP replaced by more pH insensitive Citrine successfully visualized 
cGMP dynamics in neonatal rat cardiomyocytes35, 148 and vascular smooth muscle cells.200 
Stangherlin and colleagues created targeted versions of Cygnet 2.1 to compartments where 
PKA-RI and PKA-RII are located. To do so, they fused the dimerization/docking domains 
from RIα or RIIβ to the N-terminus of soluble Cygnet 2.1 indicator, to create cGMP 
biosensors associated either with the soluble or particulate fraction of cell lysates. The 
RI_Cygnet 2.1 was homogenously distributed, and the RII_Cygnet 2.1 revealed a striated 
pattern when expressed in neonatal rat cardiomyocytes. Both sensors showed distinct cGMP 
formation patterns upon identical receptor stimulation in the two compartments.141 It is 
important to mention that Cygnet 2.1 acts very slowly and cannot reflect rapid oscillations in 
cGMP. Nikolaev et al demonstrated that the Cygnet 2.1 could not resolve pulsatile 
stimulations, as those were seen with cGES-DE5, which is based on a single cGMP binding 
domain from PDE5.196 In consequence, these “long” cGKI-based biosensors had low 
sensitivity and poor temporal resolution. To overcome these limitations, simpler versions of 
the cGKI based sensors were created, such as the cGES-GKIB. This sensor is based on a 
single cGMP binding domain (B domain of cGKI) but it is not superior to Cygnet 2.1.196 
Finally, a systematic approach to generating cGMP FRET biosensors based on single and 
tandem cGMP binding domains from cGKI and PDE5 introduced cGi500, 3000 and 6000, 
which contain the complete tandem cGMP binding domain (A + B domain of cGMP binding 





Figure 6. Fluorescent biosensors based on cGMP binding domains from cGKIα. (A) cGKI 
contains 3 major domains: the N-terminal domain, which is involved in dimerization; the cGMP binding 
domain (cGMP BD) which contains two in-tandem cGMP binding sites (A and B); and a catalytic 
domain (catalyt. dom.). The cartoon shows the domain structures of cGKIα, and selected cGMP 
indicators that are based on various fragments of cGKIα. CGY-Del1 and Cygnet 2.1 contain almost the 
full cGKI molecule, lacking only the dimerization domain, Cygnet 2.1 has an inactivated catalytic 
domain. In contrast, cGES-GKIB is based on a single cGMP binding domain, while δFlincG contains 
the two tandem cGMP binding sites. The information on domain structures was taken from
194-197
 (B) 
The cartoon shows the schematic architecture of δFlincG and its activation by cGMP, which is not 
based on FRET; binding of cGMP causes an increase in fluorescence emission intensity of circularly 
permuted EGFP (cpEGFP), modified from Nausch et al.
194
 In contrast, (C) shows the schematic 
structure of Cygnet 2.1, which is a FRET-based biosensor, the catalytic domain is not fully shown, this 
has been done to allow a better comparison between FRET-based Cygnet 2.1 and non-FRET based 
δFlincG, which lacks this domain. cGMP binds to the cGMP binding sites causes a conformational 
change that results in a more elongated molecule. The distance between FRET donor and acceptor 
increases and results in a decrease in energy transfer.           
Biosensors based on single cGMP binding domains of PDE2 and PDE5, namely GAF 
domains, have been developed. The domain structure of PDEs contains a C-terminal 
conserved catalytic domain and regulatory domains at the N-terminus.34 Five of the 11 PDE 
families have been identified as containing a tandem pair of GAF domains (N-terminal GAF-
A and a more distal GAF-B domain). However, in PDE2 cGMP binds to the GAF-B domain, 
while in PDE5 it is the GAF-A domain. cGES-DE2 is based on the single GAF-B domain of 




showed a higher selectivity for cGMP over cAMP.196 Finally, the replacement of the CFP/YFP 
FRET pair by T-Sapphire/Dimer2 led to an unexpected increase in cGMP affinity, with 
retained selectivity and rapid kinetics (Table 2, Fig. 7).198 
 
Figure 7. Fluorescent biosensors based on cGMP binding domains from PDEs. (A) PDE2 and 
PDE5 contain N-terminal cGMP binding domains (GAF-A and GAF-B) and a C-terminal catalytic 
domain. The selected biosensors are based on a single cGMP binding domain (GAF domain) from 
PDE2 or PDE5. Red cGES-DE5 contains Dimers2 (designated for simplicity as RFP) and T-Sapphire 
(GFP) as FRET pair, all shown biosensors are based on FRET. The information on domain structures 
was taken from 
34, 196
. (B) The model structure of cGES-DE2 is based on a single cGMP binding 
domain of PDE2 (amino acids E392 to A525; the crystal structure is shown) flanked by YFP and CFP, 
figure from Nikoalev et al.
196
         
Finally in 2006, Castro and colleagues reported measurements of cGMP dynamics in 
cultured adult rat cardiomyocytes using the α-subunit of rat olfactory cyclic nucleotide-gated 
(CNG) channel as a sensor for non-optical and indirect cGMP recordings. 
Electrophysiological measurements of cGMP-induced ion currents (ICNG) were performed and 
revealed compartmentalized cGMP signals. In particular, it was detected that GC-B-induced 
cGMP resides at the plasma membrane and is regulated by PDE2, while cGMP that was 
synthetized by NO-GC is located in the cytosol and under control of PDE5 hydrolytic 
activity.49 Moreover, the same group demonstrated that cGKI is involved in the cGMP 
compartmentation via a negative feedback mechanisms, using the same technical setting.201 
However, the main limitation of CNG channels as cGMP sensor remained their exclusive 







1.5 Aim of the work 
Previous studies have demonstrated that key components of cAMP signaling are associated 
with the cardiac RyR to form a local cAMP microdomain, which is involved in the regulation 
of channel function. It has been postulated that Ca2+ leak through dysregulated cardiac RyRs 
occurs in cardiovascular disease. Furthermore, there is a wealth of information that supports 
a protective role of cGMP-dependent signaling in cardiomyocytes and agents that raise 
cGMP are investigated in a large number of clinical trials. However, little is known about the 
spatio-temporal dynamics of cyclic nucleotides in functionally relevant subcellular 
microdomains, and there are no reports on FRET-based measurements of cGMP in adult 
mouse cardiomyocytes to date. The aim of the current work was to generate new transgenic 
mouse models for the visualization of local cAMP and global cGMP dynamics in adult 
cardiomyocytes. To achieve this, the dissertation contains two parts. The first part 
investigates local cAMP dynamics at RyRs, and the second studies global cardiomyocyte 
cGMP dynamics. 
Major goals of the thesis: 
1. Generation and characterization of a new transgenic mouse model with 
cardiomyocyte-specific expression of a targeted version of the cytosolic cAMP 
indicator Epac1-camps (Epac1-camps-JNC) designed to visualize cAMP at RyRs.  
2. Monitoring cAMP dynamics in the vicinity of cardiac RyRs and comparing local 
signaling with cAMP changes in the bulk cytosol using Epac1-camps-JNC and Epac1-
camps transgenic mice, respectively. 
3. Generation and characterization of a transgenic mouse model with cardiomyocyte-
specific expression of the cytosolic cGMP indicator red cGES-DE5. 
4. Monitoring cGMP dynamics in adult mouse cardiomyocytes. 
5. Analysis of cyclic nucleotide crosstalk.   
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2   Materials and Methods 
2.1   Materials 
All solutions were prepared using ultrapure water from Milli-Q Reference Water Purification 
System (EMD Millipore, Billerica, USA ) if not stated otherwise. 
2.1.1    Bacteria strains and cell lines 
E.coli (TOP 10)      (Invitrogen) 
Human embryonic kidney (HEK) 293A cell line  (Invitrogen) 
2.1.2   Mouse lines 
Epac1-camps       (Dr. Viacheslav Nikolaev) 
Epac1-camps-JNC      (this work) 
red cGES-DE5      (this work) 
β3-AR-TG and β3-AR-KO mice were provided by Prof. Jean Luc Balligand (Brussels) and 






 -/- 158 
2.1.3    Plasmid vectors 
Red cGES-DE5 in pcDNA3      (Dr. Niino, Dr. Oka, Yokohama) 
Epac1-camps-JNC in pcDNA3    (this work) 
2.1.4   Enzymes 
Pfu DNA Polymerase (2-3 U/µL)     (Promega) 
Go Taq DNA Polymerase  (5 U/µL)    (Promega) 
Restriction enzymes for molecular cloning   (New England Biolabs GmbH) 
T4 DNA ligase 400,000 U/mL     (New England Biolabs GmbH) 
Proteinase K       (Applichem) 
Liberase DH (purified Collagenase I and II)   (Roche)  
Trypsin, ready-to-use 2.5 % trypsin solution   (Invitrogen) 
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2.1.5   Antibodies 
Primary antibodies:  
anti-RYR2 mouse monoclonal antibody    (Affinity BioReagents, #MA3-916) 
anti-GAPDH mouse monoclonal antibody   (Bio Trend) 
anti-Phospho-PLN (Ser16) rabbit polyclonal antibody (Badrilla) 
anti-PLN A1 mouse monoclonal antibody   (Badrilla)  
anti-α-Tubulin mouse monoclonal antibody   (Sigma) 
anti-Phospho-VASP (Ser239) rabbit poyclonal antibody (Cell Signaling) 
anti-NO-GCα1 rabbit polyclonal antibody    (Prof. Andreas Friebe, Würzburg) 
anti-NO-GCβ1 rabbit polyclonal antibody   (Prof. Andreas Friebe, Würzburg) 
anti-GC-B guinea pig polyclonal antibody   (Prof. Hannes Schmidt, Berlin) 
Secondary antibodies: 
goat anti-mouse HRP conjugated antibody   (BioRad) 
goat anti-rabbit HRP conjugated antibody   (BioRad) 
goat anti-guinea pig HRP conjugated antibody   (Jackson Laboratories) 
goat anti-mouse Cy3 conjugated antibody   (Life Technologies) 
2.1.6   Chemicals 
Acrylamide (Rotiphoreses Gel 30)    (ROTH) 
Agarose        (peqlab) 
Ammonium persulfate (APS)     (Sigma) 
Ampicillin       (Applichem) 
ANP (mouse, rabbit, rat)      (Bachem) 
Angiotensin II        (Bachem) 
A71915 (mouse, rabbit, rat)     (Bachem) 
BAY 58-2667       (Adipoen International) 
BAY 60-7550       (Cayman) 
BNP        (Bachem)  
Bovine serum albumin (BSA)     (Sigma)  
2,3-butanedione monoxime (BDM)     (Sigma)  
Bromphenol blue       (AppliChem) 
BRL 37344       (Sigma) 
8-Br-2´-O-Me-cAMP-AM     (BioLog Life Science Inst.) 
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8-Br-2´-O-Me-cGMP      (BioLog Life Science Inst.) 
CaCl2         (Merck Millipore) 
CGP-20712A       (Sigma) 
cGMP        (Sigma) 
Cilostamide        (Sigma) 
CNP (human, porcine)     (Merck Millipore) 
Complete protease inhibitor cocktail tablets   (Roche) 
Diethylamine NONOate (DEA/NO)    (Sigma) 
Dimethylsulfoxide (DMSO)     (AppliChem) 
Ethylene glycol tetraacetic acid (EGTA)   (AppliChem) 
Ethylenediaminetetraacetic acid (EDTA)   (AppliChem) 
Ethidium bromide solution      (ROTH) 
Forane (Isoflurane)      (Abbott) 
Forskolin       (Sigma) 
Glycerol        (Sigma) 
Glycine       (Sigma) 
Goat serum       (Thermo Scientific) 
Heparin       (Ratiopharm) 
1H-[1,2,4]oxadiazolo-[4, 3-a]quinoxalin-1-one (ODQ) (Merck Millipore) 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
(HEPES)       (Sigma) 
ICI 118,551       (Sigma) 
Isoproterenol (ISO)      (Sigma) 
3-Isobutyl-1-methylxanthine (IBMX)    (Sigma) 
Kanamycin       (Applichem) 
KCl         (Merck Millipore) 
KHCO3        (Sigma) 
KH2PO4        (Merck Millipore) 
MDL-12,330A       (Sigma) 
2-Mercaptoethanol       (Sigma) 
8-methoxymethyl-3-isobutyl-1-methylxanthine (8-MMX) (Sigma)  
Melatonin       (Sigma) 
Methanol        (ROTH) 
MgCl2         (Sigma) 
MgSO4x7H2O       (Sigma) 
milk powder        (ROTH) 
100 mM dATP, dCTP, dGTP, dTTP     (Promega)  
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NaCl         (Merck Millipore)  
NaOH        (ROTH) 
Na2HPO4x2H2O       (Merck Millipore) 
NaHCO3        (Sigma) 
N,N-bis-(2-hydroxyethyl)-2-aminoethanesulfonic acid  
(BES)        (AppliChem) 
N,N,N’,N’-Tetramethylenediamine (TEMED)   (Sigma) 
Novaminsulfon Ratiopharm 500 mg/mL    (Ratiopharm) 
Paraformaldehyde (PFA)     (Sigma) 
Phenol-red        (Sigma) 
PhosphoSTOP phosphatase inhibitor cocktail tablets  (Roche) 
Polyethyleneglycol 3.000 monondisperse solution  (Fluka)  
Ponceau S       (Sigma) 
PROLI NONOate (PROLI-NO)    (Cayman) 
Rolipram       (Sigma) 
Sildenafil citrate      (Sigma)  
S-Nitroso-N-acetyl-DL-penicillamine (SNAP)  (Sigma) 
Sodium nitroprusside dihydrate (SNP)   (Sigma) 
Sodium azide        (Sigma) 
20 % Sodium dodecyl sulfate solution (20 % SDS)  (Fluka) 
SQ 22,536       (Sigma) 
Tadalafil       (Altana) 
Taurine        (Sigma) 
Tris(hydroxymethyl)-aminomethan (Tris)    (ROTH) 
10 % Triton X-100 solution, peroxide-free    (AppliChem) 
Tween20       (Sigma) 
2.1.7   Materials for cell culture 
Minimum Essential Medium (MEM)     (Invitrogen) 
Dulbecco´s Modified Eagle Medium (DMEM)  (Biochrom) 
Opti-MEM, Reduced Serum Medium, no phenol red  (Invitrogen) 
DMEM/F12, GlutaMax      (Gibco) 
Medium 199        (Sigma) 
Phosphate Buffer Saline Dulbecco´s (PBS)   (Biochrom) 
Fetal Bovine Serum, FBS Superior (FBS)    (Biochrom) 
Penicillin / Streptomycin (10.000 U/mL / 10.000 µg/mL)  (Biochrom)  
Insulin-Tranferrin-Selenium-Sodium Pyruvate supplement (Invitrogen) 
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Trypsin / EDTA Solution (0.05 %, 0.02 %)    (Biochrom) 
L-Glutamine, 200 mM      (Biochrom) 
2.1.8   Kits and others 
BCA Protein Assay Kit      (Thermo Scientific) 
[3H]-cGMP       (American Radiolabeled 
Chemicals Inc) 
Crotalus atrox snake venom      (Sigma) 
Direct PCR-Tail       (peqLab) 
Enhanced chemiluminescence reagent   (Thermo Scientific) 
iScript cDNA Synthesis Kit     (Bio-Rad) 
LB–agar powder       (Applichem) 
LB medium powder      (Applichem) 
Protein ladder (Protein marker V)     (peqLab) 
1 kb DNA-ladder       (New England Biolabs) 
100 bp DNA-ladder       (New England Biolabs) 
5x loading dye (for agarose gel electrophoresis)   (Applichem) 
Lipofectamine 2000 Transfection Reagent    (Invitrogen) 
Laminin       (Sigma) 
Qiagen Plasmid Mini Kit      (Qiagen) 
Qiagen Plasmid Midi Kit      (Qiagen) 
QIAquick Gel Extraction Kit      (Qiagen) 
RNeasy Fibrous Tissue Kit + QIAshredder    (Qiagen) 
Restriction enzymes      (New England Biolabs) 
Roticlear       (ROTH) 
10xTAE buffer       (Applichem)  
Vectashield Mounting Medium    (Vector Laboratories) 
Wheat Germ Agglutinin (WGA)    (Sigma) 
 





 Materials and Methods 
27 
 
2.2    Methods 
2.2.1   Genetic engineering 
Molecular cloning was performed to produce and modify recombinant DNA encoding for  
FRET-based biosensors. Constructs were stored in plasmid form or linearized for the 
generation of transgenic mice. 
2.2.1.1 Polymerase chain reaction  
The Polymerase Chain Reaction (PCR)202 is used to amplify DNA. A typical PCR program 
contains three major steps: First, denaturation of the double-stranded template at 94°C, 
followed by a decrease in temperature to allow oligonucleotide annealing to the single-
stranded DNA, and finally elongation by DNA polymerase at 72°C. These three steps are 
repeated 28-35 times for sequence amplification. In this work, PCR reaction was performed 
to amplify cDNA fragments for molecular cloning steps, mouse genotyping and adenovirus 
vector generation. For clonings, the PCR reaction mix contained 10 µL of 10x Pfu reaction 
buffer, 1 U Pfu polymerase, 2 µL of 10 mmol/L desoxyribonucleotide triphosphates mix 
(dNTPs), 2.5 µL forward primer dilution (final conc. 25 µmol/L), 2.5 µL reverse primer dilution 
(final conc. 25 µmol/L), 100–300 ng cDNA template and H2O up to a volume of 100 µL and 
was run on a thermocycler (Labcycler, Sensoquest, Göttingen). Annealing temperature (T) 
was adapted to the melting temperature (Tm) of the oligonucleotides (5°C below the lowest 
primer´s Tm) and the elongation time (t) was dependent on the length of the desired PCR 
product (Pfu polymerase replicates 1kbp in 2 min). 
PRC program: (94°C – 5 min, 30x(94°C – 30 s, T°C – 30 s, 72°C - t), 72°C – 7 min, 4°C - ∞) 
2.2.1.2 Agarose gel electrophoresis 
DNA fragments of varying lengths are separated by agarose gel electrophoresis, where an 
electric field is applied and negatively charged DNA molecules migrate to the anode 
according to their size. Control-digested plamid probes and mouse genotyping PCR results 
were routinely run on 1 % agarose gels at 100 V. For gel preparation 2 g agarose were 
dispersed in 200 mL TAE buffer, heated in a microwave oven to melt particles, was poured 
into a cast and supplemented with ethidium bromide for DNA staining. Samples were mixed 
with 5x loading dye and and loaded onto the gel; a DNA ladder served as a standard and 
was run in parallel. Images were aquired using a documentation system (Multi Image Light 
Cabinet Transilluminator, Alpha Innotech Corporation) and printed. In addition, gel 
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electrophoresis was performed to isolate DNA fragments, later needed for ligation reactions 
during molecular cloning. The DNA was visualized under a UV transilluminator at 312 nm, 
and a slice of agarose gel that contained the DNA fragment of interest was excised with a 
scalpel. DNA was extracted and purified using QIAquick Gel Extraction Kit, according to the 
manufacturer’s protocol and eluted in 30-50 µL H2O. 
2.2.1.3 Restriction digestion of plasmid DNA 
Type II restriction endonucleases recognize a specific nucleotide sequence and cut the 
double-stranded DNA within this sequence to generate blunt or overhanging ends.203 
Restriction digestion was performed for DNA analysis or to create a DNA fragment for further 
use. To conduct a diagnostic digest, 500 ng template (or 8 µL from a mini-preparation) were 
supplemented with 1.5 µL New England Biolabs buffer (NEBuffer), 0.5 µL of each restriction 
enzyme, 0.15 µL BSA if recommended by the manufacturer, and H2O up to a volume of      
15 µL. The digest was incubated at 37°C for 1 hour. In case of a double digest, the buffer 
was determined according to the NEBuffer performance chart for restriction endonucleases. 
For cloning, larger amounts of plasmid DNA are necessary. Therefore 6–8 µg of vector 
plasmid or template DNA were mixed with 5 µL NEBuffer, 2.5 µL of each restriction enzyme, 
0.5 µL BSA if recommended by the manufacturer, and H2O up to a volume of 50 µL. 
Preparative digests were incubated at 37°C for 4 hours, DNA was isolated by gel 
electrophoresis, extracted and eluted in 30 µL H2O (vector fragment) or 50 µL H2O (insert). 
The DNA fragments of interest were used for subsequent ligation reactions.    
2.2.1.4 Ligation reaction 
Ligation reaction is performed to insert a DNA fragment into a vector plasmid. Therefore both 
fragments were digested with the same enzymes to produce compatible ends that can be 
covalently connected by T4-DNA ligase. The ligation reaction was performed overnight at 
14°C, and the reaction mix contained 1 µL vector (1 µg), 11.5 µL insert / or digested PCR 
product, 1.5 µL of 10x ligase reaction buffer, and 1 µL T4 DNA ligase. To optimize ligation 
efficiency, different vector-to-insert ratios were run in parallel.   
2.2.1.5 Transformation of competent E. coli  
Ligation products were introduced into competent E. coli bacteria for the purpose of 
amplification using chemical transformation with 5x KCM buffer containing 500 mmol/L KCl, 
150 mmol/L CaCl2, and 250 mmol/L MgCl2. 65 µL H2O and 20 µL of 5x KCM buffer were 
mixed with 15 µL of the ligation product and incubated on ice for 5 minutes. In parallel,      
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100 µL competent bacteria were thawed on ice and added to the ligation mixture followed by 
incubation on ice for 20 minutes and a further 10 minutes at room temperature before 1 mL 
Luria-Bertani (LB) medium (without antibiotics) was added. Cells were incubated at 37°C with 
600 rpm for 45 min, pelletized, and plated on selective LB-agar plates. Recombinant bacteria 
were grown overnight at 37°C, and single colonies became visible the next day. 
• Luria-Bertani (LB) medium containing 0.5 % yeast extract, 1 % tryptone and 1 % 
NaCl: 25 g LB medium powder were dissolved in 1 L H2O, autoclaved, and stored at 
4°C. 
• Selective LB-agar plates containing 1.5 % agar in LB medium: 25 g LB–agar 
powder in 500 mL H2O, autoclaved, cooled down to 55°C, supplemented with 
antibiotics, and poured into petri dishes. 
2.2.1.6 Plasmid purification  
Following transformation, 5-10 colonies were picked, and each clone was grown in 5 mL 
selective LB medium overnight at 37°C under shaking. Plasmid DNA was isolated and 
subjected to restriction analysis to identify recombinant colonies that carried the ligated 
plasmid. To quickly isolate small amounts of plasmid DNA,  a modified protocol of the Qiagen 
Plasmid Mini Kit was used, which is based on alkaline lysis of the E.coli bacteria and 
precipitation of plasmid DNA in 2-propanol. The protocol lacks plasmid purification via anion-
exchange chromatoraphy to skip centrifugation steps. Thus, 2 mL of the overnight culture 
were pelletized and resuspended in 300 µL P1 buffer (50 mmol/L Tris, 10 mmol/L EDTA,  
100 µg/mL RNase, pH 8.0). Bacteria were lysed in 300 µL lysis buffer P2 (200 mmol/L 
NaOH, 1 % sodium dodecyl sulfate) and the solution was neutralized by adding 300 µL 
neutralization buffer P3 (3 mol/L potassium acetate, pH 5.5). The cell suspension was 
centrifuged at 13.000 rpm for 3 min and 800 µL supernatant were mixed with 700 µL 2-
propanol to precipitate DNA. The pellet was dried for 10 min and resuspended in H2O, 8 µL 
probes were used for restriction analysis. Positive colonies were further grown for increased-
scale and high-quality plasmid preparations. To do this, 50 mL selective LB medium were 
inoculated with 50 µL of the positive starter colony and grown under vigourous shaking at 
37°C overnight. Bacteria were harvested at 5.000 rpm for 5 min at 4°C and used for Qiagen 
plasmid midi-preparation according to the manufacturer’s protocol (Qiagen Plasmid Midi kit), 
which includes plasmid purification by anion-exchange chromatography. DNA was dissolved 
in H2O, and DNA concentration was determined using a UV/Vis spectrophotometer (Nano 
Drop 2.000, Thermo Scientific). 
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2.2.1.7 Measurements of DNA concentrations  
Concentration of DNA samples was measured with a UV/Vis spectrophotometer (Nano Drop 
2.000, Thermo Scientific) according to the Lambert-Beer Law. DNA was measured at 260 nm 
optical absorption, a value of 1 represents 50 µg/mL for dsDNA. Water was used as blank 
reference, sample purity ratio of A260/A280 was calculated by the software to check for protein 
impurities and values of 1.8–2.2 were accepted.     
2.2.2.   Generation of transgenic mice 
2.2.2.1 Generation of transgenic mice by pronuclear-microinjection  
Transgenic mice were generated by the pronuclear-microinjection method, where donor 
zygotes from preovulated female mice are injected with a DNA construct that randomly 
integrates into the mouse genome. The embryo is subsequently transferred into pseudo-
pregnant recipient mice, and the offspring to the foster mothers is genotyped since only 10-
20 % of the pups have integrated the transgene.204, 205 Prior to DNA injection and mouse 
breeding, the plasmid encoding the sensor construct was linearized and purified to remove 
vector backbone DNA and ions that might damage the embryo and cause poor integration 
efficiency of the fragment. 50 µg sensor plasmid was digested overnight at 37°C using 10 µL 
restriction enzyme, 20 µL reaction buffer, supplemented with BSA if recommended by the 
manufacturer in a reaction volume of 200 µL. The total digest was run on a 1 % agarose gel 
in TE buffer (10 mmol/L Tris, 0.1 mmol/L EDTA, pH 7.4, sterile filtered) to separate the 
fragment of interest, which was extracted and purified with QIAquick gel extraction kit. The 
DNA was eluted in 100 µL TE buffer, filtered via a 0.2 µm filter under sterile conditions, and 
dialyzed for 3 hours to remove impurities and ethidium bromide. Dialysis was repeated three 
more times against fresh TE buffer to further purify the DNA fragment. For pronuclear 
injection, DNA amounts of at least 200 µL with a concentration of 30 ng/µL were provided to 
the transgenic core unit of the Max-Planck Institute for Experimental Medicine in Göttingen, 
which performed pronuclear-microinjection and mouse breeding. 
2.2.2.2 PCR-based mouse genotyping  
Since Epac1-camps-JNC and red cGES-DE mouse lines were maintained as hemizygotes, 
all offspring was subjected to PCR-based genotyping to distinguish between transgenic and 
wild-type mice. Mouse tail biopsies were digested overnight in 200 µL lysis buffer (Direct 
PCR tail solution containing 0.5 mg/mL Proteinase K) at 55°C under vigorous shaking. On 
the next day, Proteinase K was inactivated at 85°C for 45 minutes, and the probes were 
 Materials and Methods 
31 
 
cooled down to 4°C. Undigested tissue and hair were sedimented, and 0.5 µL of the 
supernatant served as template for PCR amplification. The mastermix contained 4 µL of 5x 
Go Taq reaction buffer, 0.5 µL deoxynucleotide triphosphates (10 mmol/L dNTPs, each), 
0.05 µL of forward and reverse primer each, 0.2 µL Taq polymerase (Go Taq 5 U/µL) and 
14.7 µL H2O per mouse tail probe. A positive control (1 ng plasmid encoding the sensor) and 
negative control (H2O) were amplified in parallel using the same mastermix and PCR 
protocol. Following PCR reaction, probes were mixed with 5x loading dye and run on a 1 % 
agarose gel.    
Primer sequences: 
red cGES-DE5 forward   5´ TGACAGACAGATCCCTCCTAT 3´ 
red cGES-DE5 reverse   5´ GGATGCTCAGGTAGTGGTT 3´ 
Epac1-camps-JNC forward   5´ TGACAGACAGATCCCTCCTAT 3´ 
Epac1-camps-JNC reverse   5´ CATGGCGGACTTGAAGAAGT 3´ 
Program red GES-DE5 mice (~ 690 bp fragment): 
(94°C – 5 min, 35x(94°C – 30 s, 56°C – 30 s, 72°C – 80 s), 72°C – 7 min, 4°C - ∞) 
Program Epac1-camps-JNC mice (~ 340 bp fragment): 
(94°C – 5 min, 35x(94°C – 30 s, 62°C – 30 s, 72°C – 50 s), 72°C – 7 min, 4°C - ∞) 
2.2.2.3 Mouse breeding 
Transgenic and wildtype FVB/NRj mice, from Janvier Labs, Saint Berthevin, France were 
accommodated in the animal facility of the University Medical Center Göttingen and Max 
Planck Institute for Experimental Medicine, Göttingen. Mice were sacrificed to perform heart 
and cardiomyocyte isolation for experiments at the age of 2-16 months. The mouse lines 
were managed online using Pyrat and Tbase software, while technicians of the animal 
facilities took care of the mice. All animal work was performed according to institutional and 
governmental guidelines. 
2.2.2.4 Cardiomyocyte isolation 
To perform FRET measurements in single cells, cardiomyocytes from hearts of transgenic 
mice were isolated by the Langendorff method, which is based on retrograde perfusion of the 
heart through the aorta with enzyme solution.206 First, a heart perfusion system was 
assembled, which requires a peristaltic pump (for perfusion speed of 3 mL/min), a water bath 
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(the temperature of the solutions perfusing the heart should be 37°C for optimal tissue 
digestion), a canule for hanging the heart (21 G canule), and plastic tubing (Fig. 8A). 
Furthermore, a stereomicroscope was used to mount the heart onto the canule. 
 
Figure 8. Isolation of adult ventricular cardiomyocytes from mouse hearts by the Langendorff 
method. (A) Heart perfusion system containing a peristaltic pump, a canule for “hanging” the heart, a 
tubing system to allow perfusion of the heart, and a heating system. (B) The heart is removed and 
mounted on a canule to allow retrograde perfusion with enzymes via the coronary arteries, figures 
modified from Louch et al. 
206 
Before starting the isolation process, the water bath was heated up and the tubing system 
was rinsed with perfusion buffer. In addition to the perfusion buffer, two stopping buffers 
(stopping buffer 1 and 2) and a digestion buffer were prepared in advance. The Liberase 
concentration of the digestion buffer is critical and needs to be adjusted, one was working 
with concentrations of 0.021-0.042 mg/mL, depending on the size of the mouse and Liberase 
batch quality. Trypsin concentration was kept constant at 0.025 %, both enzymes were 
added shortly before starting the isolation and 2.5 mL of digestion buffer were transferred 
into a beaker. The mouse was heparinized, anesthetized and sacrificed by cervical 
dislocation, the heart was removed and mounted via the aorta onto the canule, fastened (2 
thread loops around the canule) and perfused (Fig. 8B). After 3 min, the perfusion buffer was 
changed to a digestion buffer and perfused until the buffer was used up. The heart was 
demounted and transferred into the beaker with the 2.5 ml digestion buffer inside. The atria 
were removed, and the heart was mechanically crushed for 30 seconds using small scissors. 
To inhibit the enzymatic digestion, 2.5 mL stopping buffer 1 were added. To further 
dissociate the remaining pieces of tissue by shearing force, the suspension was pulled up 
and down using a 1 mL insulin syringe without a needle for 3 min. The suspension was 
filtered through a 150 µm cell-culture mesh and the cells were sedimented at room 
temperature. The cell pellet was resuspended in stopping buffer 2. Calcium concentration 
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was increased to 1 mmol/L by stepwise addition of calcium solutions according to a 
recalcification protocol. The following solutions were added, in between each step, a break of 
4 minutes was taken: 50 µL of 10 mmol/L calcium chloride solution twice, 100 µL of             
10 mmol/L calcium chloride solution, 30 and 50 µL of 100 mmol/L calcium chloride solution. 
Following recalcification, cells were incubated at 37° for 15 min. A small pellet was visible, 
and most of the supernatant was removed; about 1 mL was left in the falcon covering the cell 
pellet. Cells were resuspended in the remaining supernatant, and 50 µL cell suspension was 
seeded on laminin-coated coverslips. Next, cells were left to settle down and adhere to the 
laminin-coated coverslips for at least 45 minutes, before cell culture medium was added. 
Cells were cultured at 37°C and 5 % CO2. More detailed protocols have been published 
recently (207, 208 AfCS Procedure protocol PP00000125, available online http://www.signaling-
gateway.org/data/cgi-bin/ProtocolFile.cgi?pid=PP00000125). For FRET measurements of 
cGMP, cardiomyocytes were incubated in medium for at least 3 hours, before starting FRET 
experiments.  
• Perfusion buffer in mmol/L: 113 NaCl, 4.7 KCl, 0.6 KH2PO4, 0.6 Na2HPO4x2H2O,  
1.2 MgSO4x7H2O, 12 NaHCO3, 10 KHCO3, 10 HEPES, 30 taurine, 10 2,3-
butanedione-monoxime, 5.5 glucose, 0.03 phenol red, pH 7.4 in H2O. 
• Liberase DH solution (4.2 mg/mL): 50 mg of Liberase DH were dissolved in 12 mL 
of sterile water, reconstituted on ice for 20 min and stored in 150 µL aliquots at -20°C.  
• Digestion buffer: 30 mL of the perfusion buffer were supplemented with 12.5 µmol/L 
CaCl2, 150-450 µL of Liberase solution, and 300 µL of 2.5 % trypsin solution. 
Enzymes were added straight before use. 
• Stopping buffer 1: 2.5 mL perfusion buffer supplemented with 50 µmol/L CaCl2 and 
1 % bovine serum albumin (BSA).   
• Stopping buffer 2: 10 mL perfusion buffer supplemented with 37.5 µmol/L CaCl2 and 
0.5 % bovin serum albumin (BSA).   
• Culture medium: Minimum essential medium (MEM) supplemented with 0.1 % BSA , 
2 mM L-glutamine, 10 mM BDM, antibiotics (100 U/mL Penicillin, 100 µg/mL 
Streptomycin) and insulin-transferrin-selenium supplement. 
2.2.3   Cell culture and transfection techniques  
2.2.3.1 Transfection of HEK 293 cells 
Most work was done in primary mouse cardiomyoctes, but also cultured Human Embryonic 
Kidney 293 (HEK 293) cells were used, which can easily be transfected with FRET 
biosensors. HEK 293 cells were grown in culture medium (Dulbecco´s MEM medium with  
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4.5 g/L glucose containing 10 % Fetal Bovine Serum (FBS), 2 mmol/L L-glutamine, 100 U/mL 
penicillin, and 100 µg/mL streptomycin) at 37°C and 5 % CO2. Cells were passaged at  70–
90 % confluency. To do this, cells were washed once with phosphate buffered saline (PBS), 
detached by trypsinization, and split in a ratio of 1:10 in medium. For transient transfection 
with FRET biosensors, cells were seeded onto autoclaved glass coverslips (24 mm, Menzel, 
Thermo Scientific) and grown in multiwell plates. In general, 6-well plates were used 
(CytoOne, 6–well plate, USA scientific) containing one coverslip per well covered with 2 mL 
culture medium; cell density on the day of transfection with calcium phosphate precipitation 
method was ~60 %. A transfection mix sufficient for one 6-well plate was prepared, 
containing 10 µg sensor plasmid DNA, 50 µL of 4.5 mol/L CaCl2 solution, 440 µL H2O, 
supplemented with 500 µL of 2x BBS buffer. The reaction mix was incubated for 10 min at 
room temperature and dispensed to equal parts onto the cells; imaging experiments were 
performed after 24 hours. Transfections using CaCl2 solutions are based on the formation of 
calcium phosphate crystals, which bind to the DNA and enter the cell by a mechanism which 
is not completely understood (probably associated with micropinocytosis). As an alternative 
method, Lipofectamine 2000 was used, a cationic lipid-mediated transfection reagent which 
allows higher transfection efficiency and quality. A protocol was performed that is sufficient 
for the transfection of a 6-well multi plate with a transfection efficiency of 75-95 %. The 
transfection mix contained 300 µL Opti-MEM, 2 µg plasmid DNA and 7 µL Lipofectamine 
2000 reagent. The mix was incubated for 20 min to allow formation of a DNA-cationic-lipid 
complex, which interacts with the negatively charged cell membrane via its cationic surface, 
to allow DNA introduction by endocytosis. On the day of transfection, cell density was ~70 % 
and the culture medium was changed to serum-reduced Opti-MEM before the transfection 
mix was added to the cells. After 2-3 hours, the Opti-MEM was replaced by culture medium, 
and cells were subjected to FRET measurements after 24 hours. 
• 2xBBS buffer containing 1.5 mmol/L Na2HPO4, 280 mmol/L NaCl and 50 mmol/L 
N,N-bis-(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES). 
2.2.3.2 Transfection of neonatal rat cardiomyocytes  
Neonatal rat cardiomyocytes were isolated from Wistar rats by Karina Zimmermann (AG 
Nikolaev, Cardiology) as described previously.209 Cells were plated onto coverslips and 
grown in culture medium (DMEM/F12 containing GlutaMax, supplemented with 1 % 
penicillin/streptomycin and 10 % FBS). The following day, cells were washed twice and the 
medium was changed to a serum-free culture medium (DMEM + M119 in a ratio of 1:4, each 
supplemented with 1 % penicillin/streptomycin and 1 % L-glutamin). On day 3, cells were 
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transfected with sensor plasmids using Lipofectamine 2000 according to the manufacturer`s 
protocol and subjected to FRET experiments after 24 hours.  
2.2.3.3 Adenoviral transduction of adult rat cardiomyocytes 
The transfection techniques described above do not work for adult cardiac myocytes.206 
Instead, viral-based transduction methods allows gene transfer not only in neonatal but also 
adult rat cardiomyocytes.210 Adenoviruses encoding Epac1-camps-JNC and red cGES-DE5 
were generated by Karina Zimmermann (AG Nikolaev, Cardiology). Adult rat cardiomyocytes 
were isolated from male Wistar rats by Tobias Goldak (AG Nikolaev, Cardiology) as 
described previously,211 seeded on laminin-coated coverslips and cultured in Medium 199 
supplemented with 5 mmol/L taurine, 5 mmol/L carnitine, 5 mmol/L creatine,  
penicillin/streptomycin and L-glutamine supplement. Myocytes were infected at multiplicity of 
infection (MOI) of 100 to 300 with adenovirus encoding FRET biosensors. The medium was 
renewed after 12 hours and FRET experiments were performed after 48 hours.  
2.2.4   Characterization of the transgenic mouse lines 
2.2.4.1 Histological analysis  
The hearts of 3 and 6 months old mice were perfused with PBS, fixed in Roti Histofix 
(containing 4% formaldehyde in PBS) overnight at 4°C, paraffin-embedded, and sectioned 
using Leica RM 2165 microtome (Leica Biosystems). For hematoxylin-eosin staining, tissue 
slides were deparaffinized and rehydrated by performing 9 washing steps (2x xylene for 20 
min, 100 % ethanol, 90 % ethanol, 80 % ethanol, 65 % ethanol, 50 % ethanol, 25 % ethanol, 
tap water; incubation for 5 min each). Heart sections were stained three times with 
hematoxylin and twice with eosin for 2 min each at the Department of Pathology, University 
of Göttingen, Medical Center. Images of stained cross-sections were acquired on a Stemi 
2000-C microscope binocular equipped with Axio Cam ICc1 and AxioVision software (Carl 
Zeiss MicroImaging, Jena, Germany). In addition, membrane stainings were carried out 
using wheat germ agglutinin (WGA) lectin for analysis of cell diameter. Cross-sections were 
incubated with WGA (75 µg/mL) in the dark for 30 min, washed three times with PBS and 
mounted in Vectashield Mounting Medium. Images were acquired using Zeiss Axiovert 200 
inverted fluorescence microscope equipped with AxioCam and appropriate filters. One 
hundred cells from 5 sections per heart were analyzed by using ImageJ program (National 
Institutes of Health, Maryland, USA). Karina Zimmermann (AG Nikolaev, Cardiology) was 
involved in the histology work.   
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2.2.4.2 Morphometric analysis 
Morphometric analysis of wildtype and transgenic hearts was performed at the age of 3 and 
6 months. Tibia length was measured using a sliding caliper, the heart weight was 
determined with an analytical balance (BP300S, Sartorius, Göttingen, Germany).  
2.2.4.3 Echocardiography 
Analysis of in vivo heart function was performed by Kirsten Koschel and Julia Steinbrecher 
(AG Lehnart, Cardiology, UMG Göttingen) using transthoracic echocardiography (Visual 
Sonics Vevo 2100, Toronto, Canada). 
2.2.5   Transverse aortic constriction surgery  
Red cGES-DE5 mice were subjected to transverse aortic constriction surgery (TAC)212 to 
study cGMP dynamics in an animal model of cardiac hypertrophy. Female transgenic mice 
(9-13 weeks of age) were split into TAC and SHAM group. The SHAM mice underwent the 
same surgical procedure without aortic constriction. Mice were anesthetized using 1.5-2 % 
isofluorane in pure O2; a surgical incision was made to uncover the aortic arch under a 
binocular macroscope using microsurgical technique. The constriction was performed 
between the first and second trunk of the aortic arch using a 6-0 polyviolene suture and a 26-
gauge to perform banding with a defined constriction. The mice were under analgesic 
therapy 3 days before the surgery and for 1 week following operation. Three days post-
surgery, the pressure gradient was measured by transthoracic echocardiography. The TAC 
and SHAM surgery was carried out by Julia Steinbrecher (AG Lehnart, Cardiology UMG 
Göttingen). 
2.2.6 Working heart experiments 
Isolated hearts were perfused via the pulmonary vein and left atrium with Krebs-Henseleit 
buffer (KH buffer) in an anterograde mode. Venous return (preload) and aortic pressure 
(afterload) were adjusted to 5 mL/min and 50 mmHg, respectively.29, 213 Following 20 min 
perfusion with KH buffer, agonists or vehicle were perfused for 10 min via the coronary 
arteries. The heart was removed and left ventricles were shock frozen in liquid nitrogen. 
Probes were split for radioimmunoassay measurements and immunoblot analysis. Working 
heart preparations were carried out by Katharina Völker and Birgit Gassner (AG Kuhn, 
Department of Physiology Würzburg) 
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• KH buffer contained in mmol/L: 118 NaCl, 4.7 KCl, 1.2 MgSO4, 1.2 CaCl2, 1.2 
KH2PO4, 25 NaHCO3, and 11 glucose. The buffer was oxygenated by gasing the 
solution with 95 % O2 and 5 % CO2. 
2.2.7   Biochemical techniques 
2.2.7.1 Cell and tissue lysis 
Cardiac myocytes were freshly isolated, sedimented in stopping buffer 2 (lacking BSA) and 
shock frozen in liquid nitrogen. Cultured HEK 293 cells or neonatal rat cardiac myoctes were 
washed once with ice cold PBS and harvested with a cell scraper. Cells were centrifuged and 
shock frozen using liquid nitrogen. Cell pellets were resuspended in homogenization buffer 
and incubated on ice for 15 min, followed by centrifugation for 5 min at 8.000 rpm and 4°C. 
Finally, the supernatant (lysate) was transferred to a new eppendorf cup and stored at -80°C, 
protein concentrations were determined by Bicinchoninic Acid Assay (BCA assay). 
• Homogenization buffer in mmol/L:  150 NaCl, 1 EGTA, 2 CaCl2, 300 sucrose, 10 
HEPES, 1 % Triton-X, pH 7.4 in H2O, supplemented with phosphatase and protease 
inhibitor cocktail (1 tablet each per 10 mL homogenization buffer). 
For tissue lysis, the heart of a mouse was quickly removed, perfused with ice cold PBS, the 
atria were removed and the ventricles were homogenized with an ultra turrax device 
(MICCRA D-1 Homogenizer, ART, Müllheim) in 500 µL homogenization buffer lacking Triton 
X detergent to avoid foam formation. After homogenization, the suspension was 
supplemented with 1 % Triton X and incubated on ice for 10 min, inverted every 2 min, 
followed by centrifugation for 5 min at 8.000 rpm and 4°C. The supernatant was transferred 
to a new eppendorf cup and stored at -80°C. Protein concentration was determined by BCA 
assay. 
2.2.7.2 Quantification of proteins with bicinchoninic acid assay 
The amount of proteins after cell or tissue lysis was quantified with the Bicinchoninic Acid 
Assay (BCA), where Cu2+ is reduced to Cu1+ by protein bonds. Cu1+ and bicinchoninic acid 
form a purple-colored complex that can be detected at 562 nm. 214 Lysates and blank were 
diluted 1:10 with H2O before 200 µL assay reagent (BCA Protein Assay Kit, Thermo 
Scientific) was added to 25 µL sample or blank dilution and incubated at 37°C for 30 minutes. 
Samples and blank were run in duplicate in 96-well format on a multi plate reader (µQuant 
microplate spectrophotometer, BIO-TEK, Bad Friedrichshall). The BSA standard curve was 
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used to determine the sample concentrations by plotting absorbance against the 
concentration.    
2.2.7.3 SDS-polyacrylamide gel electrophoresis   
Proteins were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) according to their size. Samples were supplemented with 5x SDS loading 
buffer, filled up to a total volume of 30 µL with homogenization buffer and incubated at 95°C 
for 5 min for protein denaturation. Gels were prepared in advance, samples and protein 
ladder were run at constant 100 V for about 1.5 hours in SDS running buffer using Mini 
Protean Tetra electrophoresis system from BioRad. The stacking gel was discarded and the 
separation gel subjected to immunoblot analysis. 
• Stacking gel (recipe sufficient for 2 gels): 500 µL Rotiphorese 30, 940 µL of 4x 
Tris/SDS pH 6.8 (500 mmol/L Tris, 0.4 % SDS, pH 6.8), 2.31 mL H2O, 18.8 µL of     
10 % ammonium persulfate (APS), 7.5 µL N,N,N’,N’-Tetramethylenediamine 
(TEMED). The last component was TEMED. 
• 10 % separating gel (recipe sufficient for 2 gels): 8 mL Rotiphorese 30, 6 mL of 4x 
Tris/SDS pH 8.8 (1.5 mol/L Tris, 0.4 % SDS, pH 8.8), 10 mL H2O, 96 µL of 10 % 
ammonium persulfate (APS), 36 µL N,N,N’,N’-Tetramethylenediamine (TEMED). The 
last component was TEMED. 
• 5x SDS loading buffer containing 200 mmol/L Tris 200, 6 % SDS, 15 % glycerol,  
0.3 % bromphenol blue, 10 % 2-mercaptoethanol in H2O, pH 6.7. 
• SDS-PAGE running buffer containing 25 mmol/L Tris, 190 mmol/L glycine, 1 % SDS 
in H2O, pH 8.3. 
2.2.7.4 Immunoblot analysis  
After separation, the proteins were transferred from the gel onto the blotting membrane and 
detected by immunostaining. First, the blotting sandwich was assembled, plugged into Mini 
Trans-Blot Transfer Cell from Bio-Rad, filled up with ice cold transfer buffer containing         
32 mmol/L Tris, 192 mmol/L glycine, 4 % methanol, and blotted for 2 hours by applying an 
electric field of 100 V. After the transfer, proteins were attached to the nitrocellulose 
membrane (Protran, Whatman), incubated in Ponceau S solution for 5 min and washed with 
water until clear bands were visible. The membrane was cut so that one probe could be 
screened for different proteins. To prevent unspecific binding, the probes were incubated in 
blocking solution (milk or BSA in TBS-Tween20, containing 0.1 % Tween20 in TBS buffer) for 
1 hour at room temperature, before incubation with primary antibody was done overnight in 
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the same blocking buffer at 4°C. The membrane was washed three times with TBS-Tween20 
and incubated with horseradish peroxidase (HRP)-coupled secondary antibody for 1 hour at 
room temperature. After 3 further washing steps, the membrane was incubated in enhanced 
chemiluminescence reagent (ECL, Thermo Scientific), a substrate of HRP activity, leading to 
a luminescent reaction. Images of various acquisition times (1 s-10 min) were acquired with a 
film processor (SRX 101A Konica, USA). Films (Fuji Medical X-Ray Films, Fujifilm) were 
scanned and subjected to densiometric analysis of the protein bands using Image J. To 
reprobe a protein on the same western blot, stripping with 200 mmol/L NaOH for 8 min was 
performed to remove primary and secondary antibodies from the membrane. 
Blotting sandwich: (–) sponge / 2 filter papers / gel / membrane / 2 filter papers /sponge (+) 
2.2.7.5 Phosphodiesterase hydrolytic activity assay  
PDE hydrolytic activity from lysates of cardiomyoctes was measured with an in vitro assay 
according to Thompson and Appleman as previously described.201, 215, 216 Single 
cardiomyocytes were isolated, pelletized, and resuspended in washing buffer (40 mmol/L 
Tris, pH 8.0); cell lysis was performed in 500 µL homogenization buffer (recipe see 2.2.7.1) 
and protein concentration was determined by BCA assay. 75 µg protein of each sample were 
filled up with homogenization buffer to 200 µL in the presence of the selective PDE blockers: 
10 µmol/L 8-MMX (PDE1), 100 nmol/L BAY 60-7550 (PDE2), 10 µmol/L cilostamide (PDE3), 
100 nmol/L tadalafil (PDE5), and broad-spectrum blocker 100 µmol/L IBMX. The samples 
were kept at 4°C for 5 min to get effective PDE inhibition. Next, 200 µL of reaction buffer 
containing 10 mmol/L MgCl2, 10 mmol/L 2-mercaptoethanol, 2 µmol/L cGMP, 1.5 mg/mL 
BSA, and 0.1 µCi [3H]-cGMP were added to start hydrolysis of [3H]-cGMP at 33°C. The 
reaction was finished after 10 min by addition of 200 µL stop solution (15 mmol/L EDTA, pH 
8.0) and inactivation at 95°C for 1 minute. Samples were centrifuged twice, and supernatant 
was incubated with 50 µg of Crotalus atrox snake venom at 33°C for 20 min, to hydrolyze 
5`phosphate bond of cGMP. Anion exchange chromatography was performed to separate 
uncharged guanosine (3´-and 5´-phosphate bond of cGMP was hydrolyzed due to PDE- and 
snake venom hydrolytic activity) from guanosine 3´-monophosphate, which was not 
degraded by PDE activity and still carried negative charge. The column contained AG1-X8 
resin (BioRad) to bind guanosine 3´-monophosphate while PDE-hydrolyzed [3H]-GMP was 
collected and quantified with a scintillation counter (MicroBeta2, Perkin Elmer). The effect of 
the selective PDE blockers was normalized to broad-spectrum PDE inhibitor IBMX to 
quantify the percentage each PDE family provides to total cGMP hydrolysis. 
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• Homogenization buffer (for PDE activity assay): 10 mmol/L MgCl2, 40 mmol/L Tris, 
1 % Triton-X, pH 8, supplemented with phosphatase and protease inhibitors. One 
tablet phosphatase and protease inhibitor cocktail each was added per 10 mL 
homogenization buffer. 
• Crotalus atrox snake venom: Crotalus atrox snake venom 1 mg/mL.  20 mg of 
Crotalus atrox snake venom were diluted in 20 mL H2O. 
2.2.7.6 Radioimmunoassay 
Cardiomyocytes were isolated and incubated in tyrode solution,29 containing 500 µmol/L 
IBMX, for 15 min. Stimulations with various agonists of guanylyl cyclase activity were 
performed for 10 min, followed by cell lysis using ice cold 70 % ethanol. For stimulations 
carried out in perfused working heart preparations, frozen left ventricular tissue was 
homogenized and processed analogously to single cardiomyocytes (cGMP extraction with   
70 % ethanol). Lysates were centrifuged at 3,000 x g at 4°C, and the supernatants were 
dried using a speed vacuum concentrator, resuspended in 50 mmol/L sodium acetate buffer, 
acetylated, and subjected to radioimmunoassay (RIA). For the determination of protein 
content, cell pellets of the ethanol extracts were used.29, 217 RIAs were performed by Birgit 
Gassner (AG Kuhn, Department of Physiology, University of Würzburg).   
2.2.7.7 Immunofluorescence studies  
Immunostaining of RyR2 was performed to co-localize Epac1-camps-JNC with the RyR2. 
Single sensor expressing cardiomyocytes were seeded on laminin-coated coverslips, 
washed once in pre-warmed PBS and fixed in 4 % paraformaldehyde (PFA) solution for      
10 min to immobilize RYR2 antigens, while subcellular structures were retained. Embedded 
cells were incubated with blocking solution (20 % goat serum and 0.15 % Triton X in PBS) for 
20 min to permeabilize the cells for antibody penetration and to block unspecific binding. 
Cells were washed once with PBS and incubated with primary mouse antibody against RYR2 
(1:500) for 2 hours, followed by washing step with PBS and treatment with secondary anti-
mouse Cy3 conjugated antibody for 30 min. All blocking and incubation steps were 
performed in a humidified chamber at room temperature.  
• 4 % paraformaldehyde solution (PFA): 0.4 g PFA was dissolved in 8 ml sterile PBS 
and 5 µL of 1 mol/L NaOH and heated up to 70°C in a closed up tube. The solution 
appeared clear, was cooled down to room temperature and 10 mL sterile PBS were 
added, filtered via a 0.2 µm sterile filter and stored at - 20°C. 
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• Antibody dilutions for immunochemistry: Antibodies were diluted in PBS, 
containing 1 % goat serum and 0.15 % Triton X. 
2.2.8   FRET-based measurements of cAMP and cGMP 
Typical systems for FRET-based imaging contain a source of light to excite donor fluorescent 
intensity, a beam splitter to divide emission light into two independent channels, and a 
camera to detect donor and acceptor channel intensities simultaneously (Fig. 9).  
 
Figure 9. FRET imaging setup containing a microscope stage (Zeiss Axiovert 200) equipped with a 
source of light (Polychrom V), an image splitter (Quad View beam splitter) to detect donor and 
acceptor intensities simultaneously, and a charge coupled device (CCD) camera. Picture was taken 
from Börner et al.
191
, but shows the setup in Göttingen, which was used for cGMP measurements. 
The FRET data were acquired using two different imaging setups. For most experiments, a 
monochromator-based light source was used (Polychrome V containing a 150 W xenon 
lamp, TILL photonics, Gräfelfing, Germany), so any wavelength between 320 nm and       
680 nm could be chosen for donor excitation, which made the system suitable for cGMP 
measurements with excitation of T-Sapphire at 405 nm, as well as for cAMP measurement 
using 436 nm for CFP. The imaging setup was based on a standard inverted microscope 
(Zeiss Axiovert 200), equipped with an EC Plan-Neofluar 63x/1.25 oil-immersion objective 
(Zeiss, Jena, Germany) and a wheel to switch between filter cubes. For cGMP 
measurements a filter cube equipped with a BP 405/20 excitation filter and a DCLP455 
dichroic mirror was used. For cAMP imaging one switched to a BP 436/20 excitation filter 
containing the same dichroic mirror (AHF Analysentechnik, Tübingen, Germany). Emission 
light was split into donor and acceptor channel using the Photometrics Quad View beam 
splitter (Photometrics), which implies three dichroic mirrors 500-, 535- and 565dcxr, and four 
emission filters BP487/25, BP515/30, BP550/40 and BP590/40, for cyan (CFP), green        
 Materials and Methods 
42 
 
(T-Sapphire), yellow (YFP) and red (Dimer2), respectively. Single channel intensities were 
collected with a charge coupled device (CCD) camera (CoolSNAP HQ, Roper scientific) and 
monitored online in real-time using VisiView software (TILL photonics).  
cAMP measurements at RYRs were exclusively performed on an imaging setup, which was 
based on a Nikon inverted microscope (Nikon Ti-U stage). CFP was excited with a single-
wavelength light-emitting diode (CoolLED pE-100, 440 nm), which was controlled using 
Arduino digital-to-analogue input-output board (Arduino Duemilanove). The filter cube 
contained ET436/30M excitation filter and a DCLP455 dichroic mirror (CFP/YFP filter set, 
Chroma technology, emission filter was removed), emission light was split by DV2 beam 
splitter (DualView, Photometrics), which contained 05-EM filter set (includes 505dcxr dichroic 
mirror, ET480/30M, ET535/40M emission filters) to collect cyan and yellow emission 
intensities at 480 nm and 535 nm using ORCA-03G CCD camera (Hamamatsu Photonics). 
Micro-Manager 1.4.5 software was used to control the system and to perform time-lapse 
image acquisition. 
For FRET-based measurements, cells were seeded onto coverslips (for adult 
cardiomyocytes the coverslips were coated with laminin) and cultured at 37°C and 5 % CO2 
in medium. To perform imaging experiments, cells were mounted onto the microscope, 
medium was replaced by FRET buffer and changes in cyclic nucleotide dynamics were 
monitored upon application of drugs at room temperature or 37°C. Donor and acceptor 
images were acquired simultaneously every 5 seconds.  
• FRET buffer for cardiomyocytes containing 144 mmol/L NaCl, 5.4 mmol/L KCl,      
1 mmol/L MgCl2, 1 mmol/L CaCl2, and 10 mmol/L HEPES.  
• For HEK 293 cells a FRET buffer with higher Ca2+ concentration was used, 
containing  144 mmol/L NaCl, 5.4 mmol/L KCl, 1 mmol/L MgCl2, 2 mmol/L CaCl2, and 
10 mmol/L HEPES.  
During the imaging experiment a stack of donor and acceptor images is build up. At the end 
of the experiment one can open these two stacks to draw a region of interest and transfer the 
single intensity values to Microsoft Excel software. The raw intensity data need further 
correction since emission spectra of donor and acceptor fluorescent proteins overlap 
(bleedthrough), cross-excitation of acceptor fluorescent protein and photobleaching may 
occur. However correction of cross-excitation was not performed, neither was the 
background substraction performed.   
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Bleedthrough correction was performed to calculate the corrected single channel intensities. 
To achieve this, T-Sapphire protein was expressed in HEK 293 cells alone, to measure 
fluorescent intensity in T-Sapphire and Dimer 2 emission channels upon T-Sapphire 
excitation. In this case, the ratio of T-Sapphire/Dimer 2 intensity represents the bleedthrough 
coefficient which was 0.94 for T-Sapphire spillover into the Dimer 2 channel. For cAMP 
imaging, a coefficient of 0.9 and 1 (representing 90 % and 100 % channel cross-talk) was 
determined using single CFP protein. Bleedthrough corrected FRET ratio traces were 
calculated as follows:  
For cGMP measurements: FRET ratio = (RFP-0.94xGFP) / GFP  
For cAMP measurements: FRET ratio = (YFP-0.9xCFP) / CFP  
FRET ratio =(YFP-1xCFP) / CFP (depending on the imaging 
setup)  
For simplicity, T-Sapphire was termed as GFP and Dimer2 as RFP. The ratiometric traces 
were transferred to GraphPad Prism 4 or Origin Pro 8 software, normalized to baseline, and 
corrected for photobleaching if necessary.191 FRET responses were quantified and statistics 
performed using Origin 8 software.   
2.2.9   Confocal microscopy 
Confocal images were acquired using Zeiss LSM 710 laser scanning confocal microscope 
(Carl Zeiss MicroImaging, Jena, Germany) with a Plan-Apochromat x63/1.40 oil-immersion 
objective, and analyzed using ZEN 2010 software (Zeiss). Excitation and detection settings 
for simple confocal images and immunofluorescence studies were as follows: 
T-Sapphire  (405 nm diode laser excitation, detection 490-520 nm) 
Dimer2  (561 nm diode laser excitation, detection 580-630 nm) 
YFP  (488 nm argon ion laser excitation, detection 498-555 nm) 
Cy3   (561 nm diode laser excitation, detection 569-641 nm) 
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2.2.10  Statistics 
Data were analyzed with Origin Pro 8 software and shown as means ± SE. In case of FRET 
experiments in neonatal or adult cardiomyocytes, the number of single cells (n) and 
isolations (N) was written above the graphs as n/N. To test for normal distribution, the 
Kolmorogov-Smirnov test was applied. Data, which were normally distributed were compared 
using 2-way ANOVA followed by Bonferoni post-test for multi-group comparisons, or 1-way 
ANOVA for two-group comparison. If not normally distributed non parametric tests (Kruskall-
Wallis followed by Dunns test or Mann-Whitney) were applied.208 Differences were 




3.  Results 
3.1 Real time visualization of cAMP dynamics in the vicinity of the 
RyR2 using Epac1-camps-JNC transgenic mice 
3.1.1 Design of the Epac1-camps-JNC construct for the generation of 
transgenic mice  
For FRET-based measurements of cAMP dynamics at the RyR2, the cytosolic Epac1-camps 
was fused with junctin protein to create a targeted cAMP biosensor that can monitor local 
cAMP dynamics at the RyR2 signaling complex (Fig. 10A). The first version of the Epac1-
camps-JNC sensor construct was available, containing Epac1-camps189, 193 genetically fused 
with junctin encoding sequence in pcDNA3-based vector (provided by Dr. Nikolaev). The 
construct was modified for the generation of transgenic mice expressing Epac1-camps-JNC 
in the myocardium. First, the linker region was reduced to 19 base pairs using the KpnI 
restriction sites since the original sequence, connecting the promoter with the biosensor 
encoding sequence, was too long and thus prevented transgenic sensor expression. 
Furthermore, YFP was replaced with EYFP cDNA, for increased brightness of FRET 
acceptor protein, and the modified sensor sequence was cloned into the pB-αMHC vector188 
between KpnI and XhoI restriction sites to permit cardiomyocyte-specific sensor expression. 
The insert containing the αMHC promoter, the encoding sequence, and polyadenylation 
signal was excised with NotI, gel-purified and used for pronuclear injection to create 
transgenic mice (Fig. 10B). Prior to this, one had to test the functionality of the cAMP sensor 
in living cells. Therefore, the sequence encoding the sensor protein was subcloned into a 
pcDNA3-based vector using KpnI and EcoRV restriction sites. This vector contains the 
cytomegalovirus enhancer-promoter to drive sensor expression in mammalian cells and 
allows transient transfection of HEK 293 cells with the Epac1-camps-JNC biosensor for 
FRET experiments. For imaging experiments, cells were maintained in a bath of saline buffer 
and treated with isoproterenol to increase cAMP concentrations, changes in cAMP 
concentrations were monitored by epifluorescence FRET microscopy. ISO-induced cAMP 
production led to a strong decrease in FRET ratio trace and concomitant opposing effects in 
single YFP and CFP intensity channels, indicating that the sensor was able to monitor 





Figure 10. Design of Epac1-camps-JNC construct for pronuclear-microinjection; imaging of 
cAMP dynamics in HEK 293 cells using Epac1-camps-JNC. (A) Cartoon showing the RyR2 
signaling complex and the Epac1-camps-JNC targeted to the RYR2 complex. Modified from Lehnart et 
al.
45
 (B) pB-αMHC vector containing the Epac1-camps-JNC encoding sequence. NotI was used to 
linearize the plasmid for pronuclear injections. (C) Representative FRET ratio trace recorded in HEK 
293 cells carrying Epac1-camps-JNC. Isoproterenol (ISO)-induced increase in cAMP led to a 
decrease in FRET ratio, ISO 100 nmol/L was applied. (D) Single YFP and CFP intensity recordings of 
the same cell. cAMP caused an increase in CFP intensity (donor) and a decrease in YFP (FRET 








3.1.2 Generation and characterization of Epac1-camps-JNC transgenic 
mice  
The generation of transgenic mice was performed using the pronuclear-microinjection 
method. Two rounds of injections gave rise to 10 unique PCR-positive founder lines, which 
were screened for sensor expression using fluorescence microscopy in isolated 
cardiomyocytes. The offspring of founder mice showed high levels of sensor expression, 
which was sufficient for FRET experiments. Analysis of single cardiomyocytes did not reveal 
any significant differences in fluorescent signal among the founder lines. In contrast, one 
noticed a high diversity in the number of cells that express the sensor, ranging from 5–90 % 
of total cardiomyoctes, which usually depends on the time point of transgene integration. 
One founder line (with ~70 % of total ventricular cardiomyocytes expressing the sensor) was 
established as the working line for experiments.  
The mice bred normally, appeared healthy and showed no abnormal behavior. Morphometric 
analysis, histology and analysis of cardiac function by echocardiography was performed to 
monitor any influence that sensor overexpression might have on the heart. Morphometric 
analysis of male hearts at 6 months of age did not reveal any differences between wildtype 
and transgenic hearts (Fig. 11A, B). There were also no changes in heart to body weight 
ratios at the age of 3 months detectable (5.0 ± 0.1 and 4.8 ± 0.1 for wildtype and transgenic 
mice, respectively, n=13-14), and in heart weight to tibia length ratios for 3 month old male 
mice (71.0 ± 2.0 and 69.1 ± 2.4 for wildtype and transgenic mice, respectively, n=13 each). 
Hematoxylin-eosin stainings of heart cross sections also showed no differences at 3 months 
of age (Fig. 11C).  
Staining of glycoproteins on the surface of individual myocytes was performed with wheat 
germ agglutinin to determine cell size and diameter, which were not changed in transgenic 
cells (Fig. 11D). Finally, in vivo performance of Epac1-camps-JNC mice at the age of 6 
months was assessed by transthoracic echocardiography (Table 3). Left ventricular end-
systolic and end-diastolic dimensions and functional parameters such as fractional 
shortening or ejection fraction were not altered, but one observed a slight but significant 
increase in ventricular wall thickness of transgenic hearts compared to wildtype (anterior wall 
thickness 0.80 ± 0.01 mm and 0.86 ± 0.02 mm for wildtype and transgenic mice, n=10-12). 
Increased wall thickness with no changes in functional parameters like ejection fraction 
indicate that overexpression of the transgene might have caused a mild hypertrophy without 




Figure 11. Characterization of Epac1-camps-JNC transgenic mice. (A) Heart to body weight ratios 
and (B) heart weight to tibia length ratios at the age of 6 months were not significantly increased. Data 
are means ± SE, n=13-14 each. (C) Representative cross-sections of transgenic and wildtype hearts 
at the age of 3 months stained with hematoxylin-eosin were lacking any apparent pathological 
findings, scale bar, 2 mm. (D) There was no significant difference in cardiomyocyte diameter between 
wildtype and transgenic cardiomyocytes at 6 months of age. Cell membranes were stained with wheat 
germ agglutinin, shown are data from 6 wildtype and 4 transgenic hearts with 100 cells counted for 














Parameter Wildtype animals Transgenic animals 
LV-ESD (mm) 3.35 ± 0.1 3.26 ± 0.12 
LV-EDD (mm) 4.53 ± 0.06 4.42 ± 0.09 
FS (%) 26.2 ± 1.68 26.4 ± 1.8 
EF (%) 49.8 ± 2.2 48.0 ± 2.2 
Cardiac output (mL/min) 24.9 ± 2.1 21.8 ± 1.3 
Stroke volume (µl) 53.4 ± 2.9 46.4 ± 2.4 
PWTD (mm)* 0.80 ± 0.01 0.85 ± 0.02 
AWTD (mm)* 0.80 ± 0.01 0.86 ± 0.02 
Heart rate (bpm) 459 ± 20 470 ± 17 
Table 3. Characterization of Epac1-camps-JNC mice using transthoracic echocardiography. In 
vivo performance of the heart was assessed in transgenic and wildtype mice at the age of 6 months. 
This is shown as means ± SE, n= 10-12 mice per group. LV-ESD, left ventricular end-systolic 
dimension; LV-EDD, left ventricular end-diastolic dimension; FS, fractional shortening; EF, ejection 
fraction; PWTD, posterior wall thickness in diastole; AWTD, anterior wall thickness in diastole; bpm, 
beats per minute. Significant differences (p<0.05) are indicated with asterisks. 
3.1.3 Characterization of the Epac1-camps-JNC biosensor in 
cardiomyocytes 
Following characterization of the mouse line, one had to analyze subcellular localization of 
the cAMP indicator in single cardiomyocytes. Fluorescent microscopy of freshly isolated 
Epac1-camps-JNC cardiomyocytes was performed and revealed strong YFP signals, which 
were organized in fine parallel striations with hardly any cytosolic background signal (Fig. 
12A, right). This was in clear contrast to cardiomyocytes from Epac1-camps mice,192 which 
emitted fluorescent light throughout the whole cell, lacking any hot spots of increased 
intensity levels (Fig 12A, left). These findings obviously demonstrate that the Epac1-camps is 
homogenously distributed in the cytosol, while the Epac1-camps-JNC probe cannot diffuse 
freely, but is targeted to a subcellular compartment. To analyze the association of Epac1-
camps-JNC with the RyR2 compartment, immunostainings of RyR2 in cardiomyocytes, 
carrying the Epac1-camps-JNC, were performed to co-localize sensor molecules with the 
RyR2. Confocal images demonstrated that YFP intensity, representing the sensor probe, 
completely overlapped with the RyR2 (Fig. 12C), showing that the sensor localization 
corresponds to that of the RyR2.  
In a next step, one had to confirm that the fusion of Epac1-camps with junctin protein did not 
greatly alter the affinity of the biosensors for cAMP, since it was intended to compare 




measured using 8-Br-2´-O-Me-cAMP-AM,191 a cell-permeable cAMP analogue which has the 
same affinity to Epac as cAMP and is routinely used to calibrate biosensors in 
cardiomyocytes (Fig. 12B). Both sensor probes showed similar affinities for cAMP (EC50 is 
the cAMP concentration where a half-maximal FRET response was observed; for Epac1-
camps-JNC and Epac1- camps the EC50 values were 1.15 ± 0.14 µM and 1.25 ± 0.44 µM, 
means ± SE, n= 5-9, from one mouse each). In cardiomyocytes, cytosolic cAMP levels have 
been amounted to ~ 1 µmol/L,191 which means that the sensor is already partially activated at 
basal state; furthermore, there might be differences in basal cAMP concentrations between 
cytosol and RyR2 microdomain. Hence it might be helpful to decrease intracellular cAMP to 
minimal levels, before performing dose-response titrations. Unfortunately, inhibitors of 
adenylyl cyclase such as MDL-12,330A caused significant cell damage and were not 
applicable in cardiomyocytes, in my hands. For these reasons, sensor affinity values were 
determined in HEK 293 cells that have low basal cAMP (EC50 value for Epac1-camps was 
0.95 ± 0,14 µM191 and 1.11 ± 0.24 µM, n=12 cells for Epac1-camps-JNC). Both sensors 
showed a suitable signal-to-noise ratio, while the Epac1-camps had a higher dynamic range 
(max. FRET responses to isoproterenol 100 nmol/L + IBMX 100µmol/L in cardiomyocytes 
from Epac1-camps mice was 24.2 ± 0.6 % (n=42 from 4 mice) and 13.1 ± 0.6 % (n=34 from 8 









Figure 12. Localization of the Epac1-camps-JNC in single adult cardiomyocytes and sensor 
affinity (A) Images of YFP intensity revealed a targeted subcellular localization of Epac1-camps-JNC 
(left), while the cytosolic Epac1-camps (right) is homogenously distributed throughout the whole cell. 
(B) Cardiomyocytes from Epac1-camps-JNC mice were treated with increasing amounts of 8-Br-2´-O-
Me-cAMP-AM, FRET responses are expressed as percent of maximal change (100 % is the response 
induced by 8-Br-2´-O-Me-cAMP-AM 100 µmol/L) and were plotted against the log (8-Br-2´-O-Me-
cAMP-AM) to fit a concentration-response dependency curve. Figure was calculated from 5 cells out 
of 1 isolation (C) Cardiomyocytes isolated from Epac1-camps-JNC were stained with primary antibody 
recognizing RyR2 and visualized by confocal microscopy using Cy3-labeled secondary antibody. 
Sensor probe was monitored by YFP intensity. Images of sensor probe (green) and RyR2 (red) were 
superimposed; yellow color indicates regions of overlapping intensities (left, middle). The merge 









3.1.4 FRET-based measurements of cAMP in cardiomyocytes isolated 
from Epac1-camps and Epac1-camps-JNC transgenic mice 
3.1.4.1 β-adrenergic receptor-mediated cAMP signaling  
The β-adrenergic receptor system is the predominant regulator of heart function. It does so 
by mediating the effects of endogenous catecholamines.11  β1- and β2-adrenergic receptor 
subtypes both increase cAMP by activation of adenylyl cylases via Gs-proteins.
218 To analyze 
which receptor subtype modulates cAMP levels in the RyR2 microdomain, FRET-based 
measurements of cAMP upon selective stimulation of β1-and β2-AR activity were performed 
in cardiomyocytes isolated from Epac1-camps-JNC and Epac1-camps mice. 
To activate only one receptor subtype, the non-selective β-adrenergic agonist isoproterenol 
(ISO) was applied in the presence of the β1-or β2-selective inhibitors CGP-20712A and       
ICI 118,551 respectively. It is not possible to accurately compare absolute FRET response 
detected in the cytosol with those in the RyR2 compartment since the data were acquired 
using two biosensors with slightly different characteristics, as described in 3.1.3. 
Consequently, absolute FRET responses were expressed as the proportion of the maximal 
Forskolin 10 µmol/L + IBMX 100 µmol/L response to allow a comparison of cytosolic and 
RyR2-localised cAMP fluctuations. Forskolin and IBMX strongly induce cAMP production via 
activation of adenylyl cyclases and non-selective inhibition of PDE-mediated cAMP 
degradation, respectively. The β1-AR evoked strong increases in cAMP, which were 
detectable in the cytosol and RyR2 compartment (Fig. 13A, C). In contrast, stimulation of the 
β2-AR caused only small signals, which were not present in every cell (Fig. 13B, D). There 
were no significant differences in cAMP formation in the entire cytosol versus RyR2 
compartment detectable. However, compared with the whole cytosol, β2-AR-induced cAMP 




Figure 13. β-AR-induced cAMP dynamics in the cytosol and RyR2 compartment. Single 
cardiomyocytes isolated from Epac1-camps-JNC (A, B) and Epac1-camps (C, D) mice were subjected 
to FRET experiments. Cells were pretreated with ICI 118,551 50 nmol/L to antagonize β2 AR activity 
and CGP-20712A 100 nmol/L to block β1 ARs followed by application of ISO 100 nmol/L to activate 
the unaffected receptor subtype. A decrease in the FRET ratio curve corresponds with an increase in 
cAMP. (A, C) After selective stimulation of β1ARs or (B, D) β2ARs, Forskolin (Forsk.) 10 µmol/L plus 
IBMX 100 µmol/L were applied on top to activate cAMP production. FRET responses were related to 
the maximum response (Forsk + IBMX) to compare bulk cytosolic cAMP levels with the RyR2 
compartment. (E) Quantification of FRET responses shown in A to D, means ± SE. The numbers of 
mice and cells per condition are shown above the bars (as n cells/N mice), there were no significant 






3.1.4.2 cAMP degradation by PDE hydrolytic activity at basal state  
cAMP production is counterbalanced by hydrolytic activity of PDEs, which can shape a cAMP 
signal after β-adrenergic stimulation but also regulate basal cAMP concentrations. To 
monitor the contribution of various PDE isoforms to cAMP degradation, cardiomyocytes were 
treated with selective PDE inhibitors of all major cAMP-PDE isoforms expressed in the 
murine heart, namely PDE1, 2, 3 and 4.118 Cells were challenged with 8-methoxymethyl-3-
isobutyl-1-methylxanthine 10 µmol/L to block PDE1, BAY 60-7550 100 nmol/L to inhibit 
PDE2, cilostamide 10 µmol/L to antagonize PDE3, rolipram 10 µmol/L for PDE4 inhibition, 
and IBMX 100 µmol/L to induce unselective PDE inhibition. Increases in cAMP accumulation 
upon PDE inhibition were expressed as the proportion of the response to ISO 100 nmol/L.  
Compared to other cell types, cardiomyocytes have relatively high basal cAMP levels, even 
in the absence of stimulatory catecholamines.191 PDE3 activity was found to be the main 
regulator of those basal cAMP levels, while PDE4 alone was less active, and inhibition of 
PDE1 and 2 had no effect (Fig. 14A, C). Interestingly, IBMX alone led to strong increases in 
basal cAMP (Fig. 14B, C), which exceeded a simple additive effect of PDE3 and 4 hydrolytic 
activity. It seems like both isoforms regulate basal cAMP levels in a concerted manner, while 





Figure 14. FRET-based measurements of basal cAMP-PDE activity. (A) Inhibition of PDE4 with 
Rolipram 10 µmol/L did not increase basal cAMP levels, (B) while non-selective PDE inhibition with 
IBMX 100 µmol/L raised basal cAMP levels; subsequent addition of ISO further increased cAMP 
levels. Both ratio traces were recorded in cardiomyocytes isolated from Epac1-camps-JNC mice. 
Selective PDE inhibitors were added to isolated cardiomyoctes, 8-MMX 10 µmol/L for PDE1, BAY   
100 nmol/L for PDE2, cilostamide 10 µmmol/L for PDE3, Rolipram 10 µmol/L for PDE4 and IBMX   
100 µmol/L for non-selective PDE inhibition. Subsequently, isoproterenol (ISO) was applied. (C) 
Quantification of FRET responses, shown are means ± SE, as n cells from N mice, written above the 
bar graphs. Cilostamide showed the strongest effects, while the other showed only negligible effects. 
FRET experiments were performed in cardiomyocytes from Epac1-camps and Epac1-camps-JNC. 









3.1.4.3 cAMP degradation by PDE hydrolytic activity after β-adrenergic 
stimulation 
There were no significant differences between PDE profiles in the cytosol and RyR2 
compartment at unstimulated state detectable, so one had to analyze PDE activity after 
prestimulation with ISO 100 nmol/L. β-adrenergic receptor-mediated cAMP is mainly 
restricted by PDE4 hydrolytic activity (Fig. 15B). Since stimulation with ISO 100 nmol/L led to 
a massive increase in cAMP per se, addition of the PDE4 inhibitor rolipram on top further 
strongly raised cAMP concentration to levels that were high enough to saturate the FRET 
sensors. To measure in the dynamic range of the FRET sensors, PDE4 inhibition was 
performed upon stimulation with ISO 5 nmol/L, which evoked smaller increases in cAMP than 
ISO 100 nM, allowing visualization of the complete FRET response to rolipram (233 ± 33 % 
of ISO measured in Epac1-camps; 251 ± 28 measured in Epac1-camps-JNC, n=8-9 cells 
from 2 mice each, no significant difference between cytosol and RyR2 compartment). In 
addition, it was observed that PDE3 is less active than PDE4 after β-AR stimulation, while 
PDE1 and 2 play only minor roles in murine heart (Fig 15A, B). 
 
Figure 15. cAMP-PDE activity after β-adrenergic stimulation. (A) Cardiomyocyte expressing the 
Epac1-camps-JNC was stimuled with isoproterenol (ISO) 100 nmol/L, followed by cilostamide (CIL)  
10 µmol/L to block PDE3 and IBMX 100 µmol/L to fully block all PDEs. Representative FRET ratio 
trace is shown. (B) Quantification of FRET responses. The effects of PDE blockers were related to the 
ISO response to compare cytosol (Epac1) with the RyR2 compartment (Epac1-camps-JNC), there 
were no significant differences between cytosol and RyR2 compartment detectable. Quantification of 








3.2 Real time visualization of cGMP dynamics in adult 
cardiomyocytes using red cGES-DE5 transgenic mice   
3.2.1    Generation and characterization of red cGES-DE5 transgenic mice 
Transgenic mice with cardiomyocyte-specific expression of red cGES-DE5 biosensor were 
created by random transgenesis using α-myosin heavy chain (αMHC) promoter fragment. 
Red cGES-DE5 encoding pcDNA3.1 plasmid198 was kindly provided by Dr. Niino and Dr. 
Oka, cut with KpnI and XhoI restriction enzymes and pasted into pB-αMHC vector.188 The 
fragment containing αMHC promoter, red cGES-DE5 sensor-encoding sequence, and 
polyadenylation signal, was excised with SpeI, purified and used for pronuclear injections of 
one-cell FVB/NRj mouse embryos (Fig. 16A). The cGMP indicator is based on a cGMP 
binding domain from PDE5 and flanked by green (T-Sapphire) and red (Dimer2) fluorescent 
proteins. The construct used for pronuclear-microinjection was generated by Dr. Nikolaev.  
One round of microinjections led to two founder lines that carried the transgene. Single 
cardiomyocytes isolated from these mice showed strong fluorescent intensity in T-Sapphire 
and Dimer2 channels, which was high enough for prospective FRET experiments. Different 
regions of the cell were emitting fluorescent light with similar intensities, indicating a 
homogenous cytosolic sensor distribution in living cardiomyocytes. This was in clear contrast 
to cardiomyocytes from wildtype mice, which failed to show fluorescent signals (Fig. 16B). 
Both mouse lines showed equal levels of biosensor expression with 95-100 % of total 
ventricular cardiomyocytes carrying the sensor. The mice appeared healthy, without any 
abnormalities in behavior and bred normally. One founder line was selected for future 
experiments. 
In order to detect any influence that sensor expression might have on the heart, 
morphometric, histological and echocardiographic analysis were performed. Morphometric 
analysis of hearts from transgenic and wildtype mice at the age of 6 months did not reveal 
any significant increase in heart weight (Fig. 16C, D). Also, heart weight to body weight ratios 
were monitored in mice at 3 months of age, and no differences were observed between 
wildtype and transgenic mice (4.9 ± 0.1 for wildtype and also transgenic mice, n=12-14). The 
same was true for the heart weight to tibia length ratios (68.6 ± 2.4 and 68.1 ± 1.2 for 
wildtype and transgenic mice, respectively, n=12-14). Stainings of transgenic heart cross 
sections with hematoxylin-eosin were without pathological findings (Fig. 16E) and the 
diameter of single cardiomyocytes were not altered between wildtype and transgenic groups 
(Fig. 16F). Finally, transthoracic echocardiography was performed to evaluate heart 




echocardiographic parameters observed between wildtype and transgenic mice at the age of 



















Figure 16. Generation and characterization of red cGES-DE5 transgenic mice. (A) The sensor 
construct is driven by the αMHC promoter, causing cardiomyocyte-specific expression of the red 
cGES-DE5 biosensor, which contains T-Sapphire and Dimer2 fluorescent proteins as a FRET pair. 
The cGMP binding domain was derived from PDE5. Schematic structure of the construct used to 
generate transgenic mice is shown. (B) Single isolated cardiomyocytes from red cGES-DE5 
transgenic mice revealed high levels of sensor expression in T-Sapphire (green) and Dimer2 (red) 
intensity channels, such signals were not detectable in cardiomyocytes isolated from wildtype 
littermates. Confocal images are shown. (C) Analysis of heart weight to body weight ratios (D) and 
heart weight to tibia length ratios performed at the age of 6 months did not reveal a significant 
difference between wildtype and transgenic mice. Shown are means ± SE, n= 11-22, each. (E) 
Representative cross sections of hematoxylin-eosin-stained wildtype and transgenic hearts appeared 
normal; scale bar 2 mm. (F) There were no significant differences between wildtype and transgenic 
myocyte diameter, assessed in wheat germ agglutinin-stained heart cross sections. Shown are means 




Parameter Wildtype animals Transgenic animals 
LV-ESD (mm) 3.00 ± 0.11 3.01 ± 0.08 
LV-EDD (mm) 4.20 ± 0.06 4.21 ± 0.04 
FS (%) 28.8 ± 2.1 28.5 ± 1.6 
EF (%) 50.1 ± 3.1 52.1 ± 2.2 
PWTD (mm) 0.76 ± 0.04 0.74 ± 0.01 
PWTS (mm) 1.09 ± 0.03 1.12 ± 0.03 
Cardiac output (mL/min) 20.0 ± 1.3 19.2 ± 1.3 
Stroke volume (µl) 42.9 ± 2.2 44.5 ± 1.3 
Heart rate (bpm) 465± 15 428 ± 20 
Table 4. Characterization of red cGES-DE mice using transthoracic echocardiography. In vivo 
performance of the heart was assessed in transgenic and wildtype mice at the age of 6 months. This 
is shown as means ± SE, n= 8-12 mice per group. LV-ESD, left ventricular end-systolic dimension; LV-
EDD, left ventricular end-diastolic dimension; FS, fractional shortening; EF, ejection fraction; PWTD, 
posterior wall thickness in diastole; PWTS, posterior wall thickness in systole; bpm, beats per minute. 
None of the parameters was significantly different between the groups at p<0.05. 
3.2.2.   Analysis of cGMP synthesis 
3.2.2.1 Analysis of cGMP synthesis in single adult cardiomyocytes 
Cardiomyocytes were freshly isolated from transgenic mice and subjected to FRET imaging 
experiments, which allow real time visualization of cGMP dynamics in living single adult 
cardiomyocytes. cGMP analogues219 such as 8-Br-2´-O-Me-cGMP or 8-pCPT-cGMP failed to 
evoke signals, most likely due to insufficient cell membrane permeability in cardiomyocytes. 
Techniques that permeabilize the membrane, as demonstrated with β-escin in vascular 
smooth muscle cells,194, 220 to allow calibration of red cGES-DE5 for cGMP in living 
cardiomyocytes, are not tolerated by this cell type. Therefore, it was not possible to calibrate 
the sensor directly in living cells. Nevertheless, the sensor showed high cGMP affinity (EC50 
= 40 nmol/L) and selectivity for cGMP over cAMP (>1000 fold) in vitro.198 
CNP-mediated stimulation of membrane-associated GC-B led to a strong increase in cGMP 
production, which could be monitored by a decrease in ratiometric FRET trace and 
concomitant changes in single FRET donor (T-Sapphire) and acceptor (Dimer2) intensities, 
which ran in opposing directions (Fig. 17A). At the level of single molecules, cGMP binds to 
the cyclic nucleotide binding domain, leading to a conformational change that causes an 
increase in the distance between donor and acceptor fluorescent proteins, inducing a 




Figure 17. Visualization of cGMP dynamics in single living cardiomyocytes. (A) Stimulation of a 
single isolated cardiomyocyte with CNP 100 nmol/L caused an increase in intracellular cGMP, which 
was monitored by a decrease in acceptor (Dimer2) / donor (T-Sapphire) ratio trace. Representative 
ratiometric FRET trace is shown, corrected for bleedthrough of T-Sapphire into Dimer2 channel and 
normalized to baseline. The associated raw single channel (Dimer2 and T-Sapphire) intensities are 
shown below. (B) Ratio image of a cardiomyocyte before and after stimulation with CNP, background 
fluorescence was substracted, scale bar 20 µm. (C) The model of the sensor is based on a cGMP 
binding domain and red (Dimer2) and green (T-Sapphire) fluorescent proteins as FRET pair. An 
increase in cGMP is reflected by a decrease in FRET.     
To assess GC activity, cardiomyocytes were treated with the natriuretic peptide hormones 
CNP and ANP to specifically stimulate membrane bound GC-B and GC-A, respectively. NO 
donors were used to activate NO-GC, which is mainly located in the cytosol. Stimulation of 
GC-B with CNP generated strong increases in cGMP, which could be further raised by 
subsequent inhibition of cGMP degradation with IBMX (Fig. 18A). Hence, the cGMP sensor 
is suitable to monitor GC-B activity since it is able to visualize the entire dynamic range of 
CNP-evoked cGMP concentrations (Fig. 18D).  
In contrast to strong responses upon GC-B stimulation, ANP and BNP, the ligands of GC-A, 
failed to evoke robust signals. ANP showed only small responses (Fig. 18B), which were 
present in ~ 25 % of the cells. Furthemore, BNP 100 nmol/L did not increase cytosolic cGMP 
levels (0.24 ± 0.17, n=11 cells from 3 mice). Since PDE hydrolytic activity might maintain low 
cGMP levels even in the presence of a GC-A agonist, stimulation with natriuretic peptides 
was followed by application of IBMX to overcome possible barriers of cGMP detection. 
Nevertheless, IBMX on top of ANP failed to unmask potential GC-A-mediated signals, since 
FRET responses to ANP in presence of IBMX (3.86 ± 0.51, n=9 cells from 3 mice) did not 




response to IBMX point to a source of basal cGMP production, which was negatively 
regulated by PDE hydrolyzing activity, but was not affected by activation of GC-A. 
Finally, cardiomyocytes were challenged with the NO donor S-Nitroso-N-Acetyl-D,L-
Penicillamine (SNAP) to investigate cGMP pools that were generated by NO-GC activity   
(Fig. 18C). Interestingly, SNAP failed to evoke FRET signals (Fig. 18E). To confirm the FRET 
data, analysis of natriuretic peptide- and NO-donor-mediated cGMP production was 
performed in lysates of isolated wildtype cardiomyoctes using radioimmunoassay technique, 
performed by Birgit Gassner (AG Kuhn, Würzburg, Department of Physiology). The results 
revealed strong cGMP production after CNP, while ANP induced a small increase in cGMP 






Figure 18. Measurements of cGMP synthesis in single adult cardiomyocytes. (A-C) Isolated 
cardiac myocytes were challenged with CNP 100 nmol/L, ANP 100 nmol/L or SNAP 100 µmol/L to 
stimulate GC-B, GC-A or NO-GC activity, respectively, and subsequently treated with IBMX             
100 µmol/L to block cGMP hydrolysis by PDEs. Shown are representative FRET ratio traces, a 
decrease in Dimer2/T-Sapphire FRET ratio trace (termed Ratio RFP/GFP for simplicity) describes an 
increase in cGMP. (D) Dose titration curve for CNP, (n=8 cells from 3 mice). (E) Quantification of 
FRET responses from A-C, shown are means ± SE, as n cells from N mice written above the bars. (F) 
radioimmunoassay (cGMP-RIA) measurements of guanylyl cyclase activity were performed in lysates 
of isolated cardiomyocytes. Cells were pretreated with IBMX 100 µmol/L and challenged with CNP, 
ANP, or SNAP for 10 min. Shown are means ± SE, from 3-4 mice per condition. Significant differences 






The absence of an effect of SNAP was unexpected, so other NO donors were tested that 
display faster kinetics of NO release than SNAP, such as Diethylamine NONOate (DEA/NO) 
1 µmol/L, PROLI-NONOate (PROLI-NO) 1 µmol/L, and sodium nitroprusside (SNP)             
50 µmol/L. However, these compounds (Fig. 19A-C), as well as stimulation of the β3-
adrenergic receptor with ISO 100 nmol/L in the presence of β1 / β2-AR blockade with CGP-
20712A 100 nmol/L and ICI 118,551 50 nmol/L (data not shown), failed to evoke signals. It 
has been demonstrated that NO-GC can be oxidized by ROS, leading to enzyme which is 
insensitive to stimulation with NO.90, 91, 221 In addition, it is possible that the cell isolation 
process might induce oxidant stress, and provide an explanation for absent NO donor 
effects. To exclude this, myocyte isolation and imaging experiments were performed in the 
presence of the ROS scavenger melatonin.222, 223 However, melatonin did not uncover 
DEA/NO-mediated effects, and BAY 58-2667 1 µmol/L, which has been described to activate 
oxidized NO-GC in an NO-independent manner,91, 224 also failed to evoke signals.  
 
Figure 19. Analysis of NO-GC activity. Cardiomyocytes were stimulated with compounds that 
release NO or can directly activate NO-GC, followed by IBMX 100 µmol/L. CNP 1 µmol/L served as a 
positive control. In line with the SNAP-applications (Fig. 18C, E), other NO-donors such as (A) 
DEA/NO 1 µmol/L or (B) PROLI-NO 1 µmol/L failed to evoke FRET signals. (C) Quantification of 
FRET responses of A-B. In addition, sodium nitroprusside (SNP) 50 µmol/L, and the NO-GC activator 
BAY 58-2667 (Cinaciguat) 1 µmol/L showed comparable results using the same live-cell imaging 
protocol. Shown are means ± SE, as n cells from N mice, written above the bars. Finally, cell isolation 
and experiments were carried out in the presence of the ROS scavenger melatonin 100 µmol/L to 




3.2.2.2 Analysis of cGMP synthesis and cGKI activity in a model of 
isolated working hearts 
Given the fact that signaling properties in isolated cardiomyocytes might differ from cells 
located in intact heart tissue, stimulations of guanylyl cyclases were performed in isolated, 
perfused working heart preparations.29, 115 Left ventricular tissue from hearts that were 
treated with ANP, CNP, SNAP or vehicle was subjected to cGMP-RIA and immunoblot 
analysis of cGKI activity. Working heart preparations and cGMP-RIA experiments were 
carried out by Katharina Völker and Birgit Gassner (AG Kuhn, Department of Physiology, 
Würzburg). As is the case in isolated cardiomyoctes, CNP induced the strongest increases in 
cGMP, while ANP failed to raise cGMP content (Fig. 20A). Surprisingly, SNAP evoked a 
small, but significant effect, which is most likely due to SNAP-induced cyclase activity from 
cardiac fibroblasts or vascular smooth muscle cells. Finally, strong CNP-induced increases in 
cGMP levels were associated with phospholamban (PLB) phosphorylation, which is a well-
established substrate of cGKI, while SNAP and ANP had no effect on PLB phosphorylation 
(Fig. 20B). In conclusion, strong responses to CNP and absent effect of NO-donor, both 
detected with the FRET sensor in single isolated cardiomyocytes, were no artifacts due to 
the isolation process or cell culture procedure but also present in cardiomyocytes from 
working heart preparations. 
 
Figure 20. Analysis of cGMP synthesis and cGKI activity in isolated, perfused working heart 
preparations. (A) Living wildtype hearts were removed and perfused for 10 min with PBS vehicle, 
CNP 100 nmol/L, ANP 100 nmol/L, or SNAP 100 µmol/L through the pulmonary vein. After perfusion, 
left ventricular tissue was split for cGMP-RIA and immunoblot analysis. Total cGMP content in the left 
ventricle was assessed by cGMP-RIA. Shown are means ± SE, from 4-5 hearts each. (B) In addition, 
tissue samples were subjected to immunoblot analysis of cGKI activity. Probes stimulated with CNP 
showed high levels of phospholamban phosphorylation (P-PLB), while tissue treated with vehicle, 
SNAP and ANP did not reveal P-PLB. GAPDH, α-tubulin and total phospholamban (PLB) were used 





3.2.3   Analysis of basal cGMP formation 
3.2.3.1 Analysis of basal NO-GC and GC-A activity 
SNAP and other drugs that were reported to stimulate NO-GC activity did not increase cGMP 
levels in adult cardiomyocytes, but inhibition of NO-GC with 1H-[1,2,4]oxadiazolo-[4,3-
a]quinoxalin-1-one (ODQ) 50 µmol/L led to an increase in FRET ratio, which represents a 
decrease in cGMP concentrations (Fig. 21A). The findings that ODQ evoked a decrease in 
cGMP levels, while inhibition of cGMP hydrolysis caused an opposing effect, namely an 
increase in cGMP (Fig. 21B), supports the thesis that basal cGMP production must occur 
and is counterbalanced by PDE hydrolytic activity. However, basal cGMP levels could be 
amounted to ~10 nmol/L using dose response titration in vitro198 and maximal FRET 
responses. The method for the calculation of intracellular cyclic nucleotide concentrations 
using FRET-based biosensors was described previously in detail by Börner and 
colleagues.191 In addition, cardiomyocytes preincubated with ODQ showed significantly 
decreased responses to IBMX. In contrast, GC-A inhibition with A71915 did not decrease 
basal cGMP levels, while basal GC-B activity could not be tested since the only well-
established and specific GC-B inhibitor HS-142-1, was not available225. These findings 
suggest that basal cGMP levels are most likely produced by NO-GC.    
 
Figure 21. Basal cGMP production is regulated by NO-GC activity. (A) Inhibition of NO-GC with 
ODQ 50 µmol/L induced a decrease in basal cGMP levels, which is represented by an increase in 
ratiometric FRET trace. Subsequent inhibition of PDE hydrolytic activity with IBMX 100 µmol/L evoked   
responses that showed a reduction in the amplitude compared with IBMX-induced response in the 
absence of ODQ. (B) To facilitate the comparison, the response to IBMX alone from Fig. 23E is 
shown. The GC-A inhibitor A71915 failed to decrease basal cGMP levels. Shown are means ± SE. 
The numbers of single cells and mice are shown above the bars (as n cells/N mice). Differences are 





3.2.3.2 Basal cGMP levels are regulated by β3-adrenergic receptors  
Red cGES-DE5 mice were crossbred with β3-AR-TG and β3-AR-KO mice to elucidate the 
involvement of the β3-adrenergic receptor in the regulation of basal cGMP levels. As 
mentioned above, stimulation of the β3-AR failed to evoke signals, but the ODQ-induced 
responses were significantly stronger in β3-AR-TG compared to wildtype littermates; β3-AR-
KO revealed smaller ODQ effects (Fig. 22). In conclusion, the β3-adrenoceptor is involved in 
basal NO-GC-mediated cGMP production since the β3-AR-TG mice had increased basal 
cGMP levels, while the β3-AR-KO mice showed decreased cGMP levels.  
 
Figure 22. The β3-AR participates in the regulation of basal cGMP levels. Red cGES-DE5 mice 










). β3-AR-TG mice are on C57/Bl6 background, while the red cGES-DE5 are 
FVB/NRj mice. To exclude differences among the mouse strains, control mice were generated by 
crossbreeding wildtype littermates of β3-AR-TG with red cGES-DE5 mice. β3-AR-KO mice, which were 





). ODQ 50 µmol/L was applied. Shown are means ± SE. The numbers 
of single cells and mice are shown above the bars (as n cells/N mice). Differences are statistically 
significant at p<0.01. 
3.2.4   Analysis of cGMP degradation by PDE hydrolytic activity   
3.2.4.1 FRET-based measurements of basal cGMP-PDE hydrolytic activity  
PDEs mediate cyclic nucleotide degradation, with four cGMP-PDE families (PDE1, 2, 3 and 
5) expressed in the murine heart. To investigate which PDE families are involved in the 
regulation of basal cGMP, single cardiomyocytes were treated with family-specific PDE 
inhibitors. 8-MMX 10 µmol/L was used to inhibit PDE1, the selective inhibitors BAY 60-7550 
100 nmol/L, cilostamide 10 µmol/L, and tadalafil 100 nmol/L were used to block PDE2, PDE3 
and PDE5, respectively. IBMX 100 µmol/L was applied on top of selective blockers as a 
positive control to inhibit total cGMP hydrolysis. Inhibition of PDE1 and PDE5 could not raise 
cytosolic cGMP, the effects elicited by BAY 60-7550 (PDE2) were very weak and close to 




cilostamide were detected, which increased cGMP levels to the same extent as IBMX (Fig. 
23C, E). Thus, PDE3 accounted for ~100 % of total cGMP hydrolyzing activity and was the 
major cGMP-PDE controlling the basal cGMP hydrolysis. 
Figure 23. FRET-based measurements of basal cGMP-PDE activity. (A) Selective PDE inhibitors 
were added to isolated cardiomyocytes, 8-methoxymethyl-3-isobutyl-1-methylxanthine 10 µmol/L (8-
MMX) to inhibit PDE1, (B) BAY 60-7550 100 nM (BAY) for PDE2, (C) cilostamide 10 µmol/L (CIL) to 
block PDE3 (D) and tadalafi 100 nmol/L (TAD) to inhibit PDE5. After selective PDE-inhibition, cells 
were challenged with IBMX 100 µmol/L as a positive control. Cilostamide showed the strongest 
effects. (E) Quantification of FRET responses from A-D; shown are means ± SE as n cells from N 





3.2.4.2 FRET-based measurements of cGMP-PDE hydrolytic activity in 
the presence of cGMP and cAMP agonists 
Next, the effects of selective PDE blockers in the presence of agents that raise cGMP or 
cAMP levels were investigated. It was felt that this might better reflect physiological 
conditions and those studies permit a comparison of PDE profiles recorded at basal and 
stimulated state. Cardiomyocytes were prestimulated for 5 minutes with the cGMP-elevating 
ligands CNP, ANP or SNAP and subsequently challenged with PDE blockers (Fig. 24A-C). In 
the presence of cGMP agonists, the PDE profiles did not differ from those recorded under 
resting conditions (Fig. 23E). Cilostamide-sensitive PDE3 remained the major regulator of 
cGMP hydrolysis, while inhibition of the other PDE families failed to induce clear FRET 
signals.  
Since pretreatment with cGMP ligands did not cause any changes in PDE activity profile, 
PDE hydrolytic activity was reanalyzed in the presence of ISO 0.1 nmol/L, to mimic moderate 
catecholamine-induced cAMP levels present in a healthy heart. Within a context of elevated 
cAMP, it is worth mentioning that PDE3 is designated as the cGMP inhibited PDE since it 
has dual activity and cAMP can act as a competitive substrate to cGMP turnover.118 To test 
whether PDE3 effect is still detectable when cAMP levels are increased, cells were 
prestimulated with ISO 0.1 nmol/L before PDE inhibitors were applied (Fig. 24D). 
Cilostamide-induced effects were reduced to half the amount of those detected in the 
absence of ISO (FRET response to cilostamide in the absence and presence of ISO, 
respectively, 4.1 ± 0.8 vs 1.9 ± 0.4, see Fig. 23E and 24D). Hence, it became possible to 
observe a clear decrease in cGMP hydrolytic activity of PDE3 when a competitive substrate 
was present. Nevertheless, PDE3 effects were still stronger than those of the other PDE 
inhibitors.     
Finally, cardiomyoctes were pretreated with BNP and angiotensin II to simulate a 
neurohormonal activation status that occurs in patients with heart failure, where both 
peptides are strongly upregulated.152, 226 Again, the PDE profile looked similar to those 
recorded in the absence of BNP and Angiotensin II, confirming the predominant role of PDE3 





Figure 24. FRET-based measurements of cGMP-PDE activity at prestimulated states. Single 
isolated cardiomyocytes were prestimulated for 5 minutes with the cGMP-stimulating agents (A) ANP 
100 nmol/L, (B) CNP 100 nmoL/L, (C) or SNAP 100 µmol/L and treated with selective PDE inhibitors, 
as described in Fig. 23. There were no differences among the PDE profiles, and PDE3 remained the 
major cGMP-PDE. (D) Cells were pretreated with isoproterenol 0.1 nmol/L to raise cytosolic cAMP 
levels, which served as a competitive substrate. cGMP hydrolytic activity of PDE3 was decreased. (E) 
Preincubation with angiotensin II (AngII) 100 nmol/L and BNP 100 nmol/L served as a model for heart 
failure. Shown are means ± SE, as n cells from N mice, written above the bars; significant differences 






3.2.4.3 Measurements of cGMP-PDE hydrolytic activity using an in vitro 
assay  
In order to verify the FRET data on cGMP-PDEs, a classical in vitro assay was performed 
according to Thompson and Appleman. PDE hydrolytic activity was measured in lysates of 
cardiomyoctes isolated from transgenic and wildtype mice at cGMP 1 µmol/L.49, 215 The assay 
revealed a dominant role of PDE2 and PDE5, while inhibition of PDE3 showed only minor 
effects (Fig. 25). These findings were contradictive to the FRET data, which showed PDE3 
as the major cGMP-PDE. 
 
Figure 25. Measurements of PDE hydrolytic activity with a biochemical in vitro assay according 
to Thompson and Appleman. PDE activity was assayed in lysates of cardiomycytes isolated from 
wildtype and transgenic mice at 1 µmol/L cGMP. The effect of the selective PDE blockers was 
normalized to IBMX to quantify the percentage each PDE family provides to total cGMP hydrolysis. 
PDE2 and PDE5 were strongly involved in cGMP hydrolysis. Shown are means ± SE, from 3-4 mice 
per condition.    
3.2.5 FRET measurements of cGMP in a model of moderate pressure-
overload induced hypertrophy  
To combine the live cell imaging approach with an experimental model of cardiovascular 
disease, transgenic mice underwent transverse aortic constriction (TAC) surgery to induce 
cardiac hypertrophy and remodeling. Mice were split into TAC operated group and control 
animals, which underwent the same operation procedure without aortic constriction (SHAM), 
to compare cGMP signaling in diseased versus healthy cardiomyocytes. Echocardiography 
at 8 weeks post TAC/SHAM operation demonstrated significant increases in heart weight to 
body weight ratios, wall thickness, and left ventricular end-systolic dimensions, with small but 
not significant reductions in functional parameters such as ejection fraction and fractional 




Parameter SHAM animals TAC animals 
Pressure gradient (mmHg) 4.7 ± 0.5 84.8 ± 4.7* 
HW/BW ratio (mg/g) 4.34 ± 0.27 6.58 ± 0.44* 
AWTD (mm) 0.74 ± 0.04 1.11 ± 0.05* 
PWTD (mm) 0.73 ± 0.04 1.10 ± 0.05* 
LV-ESD (mm) 2.85 ±  0.10 3.24 ± 0.12* 
LV-EDD (mm) 3.91 ± 0.08 4.24 ± 0.03* 
FS (%) 27.22 ± 1.68 23.7 ± 2.34 
FAS (%) 44.65 ± 1.49 41.27± 3.08 
EF (%) 50.91 ± 1.43 47.26 ±2.40 
Heart rate (bpm) 443 ± 20 483 ± 24 
Table 5. Characterization of transgenic mice after TAC and SHAM surgery using transthoracic 
echocardiography. Transgenic mice at the age of 9-13 weeks underwent transverse aortic 
constriction (TAC) or control (SHAM) operation. Shown are means ± SE, n= 6 mice per group, 
significant differences (p<0.05) are indicated with asterisks. HW/BW ratio, heart weight body weight 
ratio; AWTD, anterior wall thickness in diastole; PWTD, posterior wall thickness in diastole LV-ESD, 
left ventricular end-systolic dimension; LV-EDD, left ventricular end-diastolic dimension; FS, fractional 
shortening; FAS, fractional area shortening; EF, ejection fraction. 
Since only a limited number of operated mice was available, it was decided to focus on    
GC-B-induced cGMP signaling, basal NO-GC activity and PDEs. A strong contribution of 
cilostamide-sensitve PDE3 to total cGMP-PDE hydrolytic activity could be observed (Fig. 26). 
Furthermore, small FRET responses upon PDE5 inhibition with tadalafil in TAC cells, which 
were absent in control cardiomyocytes (SHAM), were detected, indicating an upregulation of 
PDE5 activity during cardiac hypertrophy. Finally, there was no difference in GC-B activity 







Figure 26. cGMP dynamics in a model of cardiac hypertrophy. Mice were subjected to transverse 
aortic constriction (TAC) surgery to induce hypertrophy, SHAM-operated mice served as controls. 
Myocytes isolated from TAC and SHAM mice were subjected to FRET experiments. 8-MMX 10 µmol/L 
was used to block PDE1, BAY 60-7550 100 nmol/L (BAY) for PDE2, cilostamide 10 µmol/L for PDE3, 
tadalafil 100 nmol/L (TAD) for PDE5 and IBMX 100 µmol/L (nonselective). CNP 100 nmol/L was 
added on top of IBMX 100 µM. An upregulation of PDE5 hydrolytic activity in the TAC model was 
observed. Shown are means ± SE, as n cells from N mice, written above the bars, significant 
differences (p<0.05) are indicated with asterisks.   
3.2.6   Analysis of cGMP/cAMP crosstalk in adult mouse cardiomyocytes 
Analysis of cGMP dynamics in cardiomyocytes from red cGES-DE5 mice revealed a major 
role of PDE3 in cGMP breakdown. There is considerable evidence suggesting an interplay 
between cAMP and cGMP signaling,141, 227 mediated via PDE3 activity and it is worth to 
emphasize again that PDE3 is known as the “cGMP inhibited PDE”, since cGMP can act as 
an inhibitor to cAMP catabolism.118 It was investigated whether cGMP might influence          
β-adrenoceptor-mediated cAMP signals through inhibition of PDE3. To study cyclic 
nucleotide crosstalk, FRET measurements of cAMP dynamics were performed in adult 
cardiomyocytes isolated from Epac1-camps mice,192 which express the FRET-based 
biosensor for cAMP, Epac1-camps.189, 193  
Cardiomyoctes were stimulated with ISO 100 nmol/L to raise cAMP concentrations by 
activation of β-adrenergic receptors; a decrease in FRET ratio trace indicates an increase in 
intracellular cAMP. Next, cAMP dynamics were monitored upon application of various 
agonists of guanylyl cyclase activity to assess which cGMP signaling cascade affects cAMP 
concentrations. Application of CNP to stimulate GC-B further increased cytosolic cAMP 
levels (Fig. 27A), which could be quantified as ~ 50 % of maximal PDE inhibition with 
cilostamide 10 µmol/L (Fig. 27E, F). Activation of GC-A trough ANP also increased cAMP 
generation (Fig. 27B), but the signals detected were significantly smaller than those evoked 
by CNP (Fig. 27F). Stimulation of NO-GC with SNAP could not increase cAMP levels. In the 




receptor-induced cAMP levels were not detectable (Fig. 27C, D), demonstrating that PDE3 
regulates GC-A and GC-B-mediated cGMP/cAMP crosstalk after β-adrenergic stimulation. 
In addition to PDE3-mediated cAMP/cGMP interplay, PDE2 has been shown to be involved 
in crosstalk of those cyclic nucleotides.35, 141 cGMP stimulates PDE2 hydrolytic activity and 
thereby leads to a decrease in cAMP levels. Thus, activated cAMP catabolism of PDE2 
might mask or even prevent a PDE3-mediated increase in cAMP. To test this hypothesis, 
cells were prestimulated with the PDE2 inhibitor BAY 60-7550 to evaluate if this might further 
increase CNP-induced cAMP generation. There was no additive effect on cAMP 
concentrations elicited by CNP (115.9 ± 4.4 % of ISO, n=9 cells from 3 mice) in the presence 
of BAY 60-7550 compared to cardiomyocytes that were solely stimulated with ISO and CNP 
(118.1 ± 2.8 % of ISO, n=28 cells from 6 mice, Fig. 27F). This confirmed that PDE3 conveys 
CNP-mediated cAMP/cGMP crosstalk after β-adrenergic stimulation, while PDE2 is not 
involved in the regulation of this specific cAMP/cGMP interaction.  
Strong effects of CNP on cAMP generation were measured after β-adrenergic stimulation, 
while CNP alone in the absence of ISO failed to induce cAMP generation (0.38 ± 0.38 % of 
ISO, n=13 cells from 2 mice, ISO application followed CNP and served as positive control). 
This was expected, since cilostamide can only evoke strong signals after prestimulation with 
ISO (Fig. 27E). Hardly any signals were detectable at basal state (ISO + CIL 139 ± 4 % of 
ISO versus CIL basal 8 ± 2 % of ISO, n=11-13 cells from 3 mice each). 
Finally, in contrast to natriuretic peptides, SNAP alone could not induce an increase in cAMP, 
but in the presence of PDE5 inhibition using tadalafil (TAD), small increases in cytosolic 
cAMP could be observed (Fig. 27F), while ANP and CNP-induced cAMP could not be further 
increased by TAD. In summary, stimulation of GC-B by CNP evokes a strong increase in 
cytosolic cGMP that can directly inhibit PDE3 hydrolytic activity and thus increase cAMP 









Figure 27. FRET measurements of cGMP/cAMP crosstalk. Imaging of cAMP dynamics using 
cardiomyocytes from Epac1-camps transgenic mice. A decrease in YFP/CFP ratio corresponds to an 
increase in cAMP. (A) CNP 100 nmol/L (B) and ANP 100 nmol/L further increased cAMP after           
β-adrenergic stimulation with isoproterenol 100 nmol/L (ISO). (C, D) Natriuretic peptide-induced cAMP 
generation was due to inhibition of PDE3, since preincubation with cilostamide 10 µmol/L (CIL) for      
3 min blocked CNP and ANP effects. (E) Cilostamide on top of ISO served as a positive control. Final 
application of IBMX 100 µmol/L (A-E) led to a strong signal, indicating that effects evoked by CNP, 
ANP and CIL were in the dynamic range of the sensor. (F) Quantification of FRET responses from A-
E, shown are means ± SE, as n cells from N mice, written above the bars, significant differences 
(p<0.05) are indicated with asterisks. Inhibition of PDE5 with tadalafil 100 nmo/L (TAD) induced small 
increases in cAMP upon SNAP application. PDE 5 did not affect ANP-and CNP-induced cAMP 







Figure 28. Schematic diagram showing cGMP/cAMP interplay mediated by PDE3. Stimulation of 
GC-B with CNP leads to a robust increase in cytosolic cGMP levels. This pool of cGMP is a 
competitive substrate to cAMP hydrolysis of PDE3 and can be described as a PDE3 inhibitor. Thus, 
GC-B-induced cGMP blocks PDE3 activity and raises cAMP levels after β-adrenergic activation. GC-A 
can also induce cGMP levels that modify PDE3 activity. NO-GC-mediated cGMP is tightly controlled 
by PDE5 hydrolytic activity.  
3.2.7 Measurements of cGMP synthesis in neonatal and adult rat 
cardiomyocytes  
Neonatal rat cardiomyocytes were transfected with red cGES-DE5 encoding sensor plasmid 
and subjected to FRET measurements. Stimulation of GC-A and GC-B activity with 
natriuretic peptides resulted in small increases in cGMP upon ANP and strong CNP-evoked 
signals, which were quite similar to those detected in adult mouse cardiomyocytes (Fig. 29A). 
Interestingly, clear responses to NO-GC stimulation were detected with SNAP 100 µmol/L in 
neonatal rat cells, as reported by others.141, 148 These SNAP responses were absent in adult 
cardiomyocytes (Fig. 18E). Immunoblot analysis of NO-GC expression revealed a 2.9 ± 0.2-
fold higher NO-GC protein levels in neonatal versus adult cardiomyocytes, which might 










Figure. 29 FRET measurements of cGMP production in neonatal rat cardiomyocytes, NO-GC 
expression levels in neonatal versus adult cardiomyocytes, and CNP-induced increase in 
cGMP detected in adult rat cardiomyocytes. (A) Neonatal rat cardiomyocytes transiently 
transfected with red cGES-DE5 showed a robust FRET response to SNAP 100 µmol/L, which was not 
detectable in adult mouse cardiomyocytes (see Fig. 18E). Stimulation with ANP 100 nmol /L and CNP 
100 nmol/L also increased cGMP synthesis, IBMX was added with a concentration of 100 µmol/L. 
Shown are the quantifications of FRET responses as means ± SE, as n cells from N isolations, written 
above the bars. (B) Immunoblot analysis of NO-GC expression in neonatal versus adult 
cardiomyocytes. Expression levels were compared with 2, 10 and 50 ng recombinant NO-GCβ protein. 
Neonatal rat cardiomyocytes (mouse hearts are too tiny for isolation protocol) express 2.9 ± 0.2-fold 
more NO-GC than adult mouse cardiomyocytes (mean ± SE). (C) Isolated adult rat cardiomyocytes 
were infected with adenovirus encoding red cGES-DE5 and subjected to FRET experiments. 
Representative recording is shown: CNP 1 µmol/L + IBMX 100 µmol/L caused a strong increase in 
cGMP.     
Finally, adult rat cardiomyocytes were infected with red GES-DE5 adenovirus and revealed 









4   Discussion 
4.1 Real time visualization of cAMP dynamics in the vicinity of the 
RyR2 using Epac1-camps-JNC transgenic mice 
4.1.1 Generation and characterization of Epac1-camps-JNC transgenic 
mice 
A new transgenic mouse model was generated to allow live cell imaging of cAMP dynamics 
in vicinity of the cardiac ryanodine receptor (RyR2). To do so, a targeted FRET-based 
biosensor was created by the fusion of cytosolic Epac1-camps with junctin molecule. It is 
established that junctin is associated with the RyR2, and direct binding interactions of both 
proteins were identified.54, 228, 229 The RyR2, calsequestrin, triadin and junctin form a 
quaternary complex that facilitates Ca2+ release from the SR. A functional role of junctin in 
Ca2+ cycling was proposed.229 However, cardiomyocyte-restricted sensor expression did not 
affect heart performance but caused a mild compensated hypertrophy revealed by 
significantly increased wall thickness (see Table 3). In a previous report, 10-fold 
overexpression of junctin, using the same promoter and mouse background, caused mild 
hypertrophy with slightly impaired relaxation, a 30 % reduction in the expression levels of the 
RyR2, and almost unaffected Ca2+ transients.230 Yet a 30-fold overexpression caused a much 
more severe phenotype.231 However, Ca2+ transients and expression levels of junctional 
proteins were not investigated in the Epac1-camps-JNC transgenic mice, since the decision 
was made to focus on the red cGES-DE5 mouse model. The fact that the Epac1-camps-JNC 
mice develop modest hypertrophy represents a certain limitation, since it was initially 
intended to study cAMP dynamics during cardiac hypertrophy after aortic banding, as this 
was done with the red cGES-DE5 mice. Here, one can consider the possibility to cross 
Epac1-camps-JNC mice into junctin null background using junctin knock-out mice.232    
4.1.2 Characterization of the Epac1-camps-JNC biosensor in 
cardiomyocytes 
The Epac1-camps-JNC represents a targeted version of the cytosolic FRET-based Epac1-
camps to permit cAMP detection not virtually everywhere within the cell, but with a spatially 
highly defined resolution. Epifluorescence images of cardiomyocytes expressing Epac1-
camps-JNC showed a striated localization of the biosensor, which was in clear contrast to 
cardiomyocytes from Epac1-camps mice emitting fluorescent light throughout the whole cell 




cardiomyocytes, giving good evidence that the sensor is associated with the RyR2 (see Fig. 
12B). Nonetheless, it is important to consider that co-localization and other methods for the 
analysis of protein interactions are of only limited value for this study, since they do not 
provide the essential information whether the sensor and the investigated cAMP 
microdomain actually overlap or not. Thus, association of the biosensor to the RyR2 does not 
imply that the sensor and, even more important, its cAMP binding domain sits in the right 
position, namely in the cAMP compartment that is supposed to regulate RyR2 function. 
Dose-response titrations in cardiomyocytes and HEK 293 cells confirmed that fusion of the 
Epac1-camps with junctin molecule did not alter its affinity for cAMP (see 3.1.3). This finding 
was highly relevant, since it was intended to compare cytosolic cAMP dynamics (recorded 
with the Epac1-camps) with the cAMP dynamics at the RyR2 (measurements carried out with 
the Epac1-camps-JNC). However, the Epac1-camps-JNC showed smaller signal changes 
compared with the Epac1-camps. This is illustrated by the fact that ISO + IBMX induced a  
13 % change in FRET using Epac1-camps-JNC and a 24 % change in FRET was observed 
with the Epac1-camps (see 3.1.3). One can expect such a signal decrease since the Epac1-
camps-JNC contains the junctin protein probably influencing the conformational movement 
upon cAMP binding. Thus, for the comparison of cAMP fluctuations in the cytsosol and the 
RyR2 associated compartment, one cannot consult absolute changes in FRET, but it is 
necessary to relate the data to physiological values (such as an ISO response, see Fig. 15). 
In conclusion, the in vitro characterization of Epac1-camps-JNC gave proof that the 
biosensor was promising for the visualization of local cAMP dynamics at RyR2 and that a 
comparison of cAMP dynamics recorded with its untargeted predecessor Epac1-camps is 
possible.      
4.1.3   FRET-based measurements of cAMP synthesis 
Classical signaling of β1-and β2-adrenergic receptors involves the formation of cAMP. It was 
demonstrated by Nikolaev et al. that the β1-AR subtype shows a broad distribution on the 
membrane, while the β2-AR is locally restricted in the T-tubular invaginations.
233 Furthermore, 
it was shown that the β1 subtype induces a major increase in cAMP throughout the whole 
cell, wheras the β2-initiated signals are spatially highly confined.
188 Indeed, robust increases 
in cAMP content were detected upon selective stimulation of β1-ARs using both biosensors 
(see Fig. 13). In contrast, the β2 signals were absent in almost all cardiomyocytes isolated 
from Epac1-camps-JNC, while very small β2 responses were observed in the Epac1-camps 
mice. There were no significant differences between the RyR2 microdomain and the bulk 
cytosol. Yet, one might postulate that the β2-signals do not reach the biosensor targeted to 
the RyR2, while there were very small responses detectable in ~50 % of cardiomyocytes 




slightly different characteristics and the Epac1-camps-JNC shows significantly smaller 
changes in FRET signal and a decreased signal-to-noise ratio, these differences are most 
likely due to the variations in biosensor properties but do not reflect differences in physiology 
of cAMP signaling. A pair of biosensors with increased affinity for cAMP, for instance Epac2-
camps-JNC and Epac2-camps might help resolve this issue. 
4.1.4   FRET-based measurements of cAMP degradation 
It was demonstrated that PDE4D3 and other key components of cAMP signaling (PKA and 
phosphatases) are associated with the RyR2 via mAKAP and form a cAMP microdomain that 
regulates the RyR2.50, 51 Furthermore, it was postulated that cardiac remodeling, which 
occurs during heart failure, causes depletion of PDE4D3 form the microdomain leading to 
PKA-mediated hyperphosphorylation of the RyR2 at single serine 2808 and associated Ca2+ 
leak.50 Finally one has to consider that global cAMP levels were amounted to ~10 µmol/L, 
whereas the affinity of PKA is in the range of 10 nmol/ –100 nmol/L in vitro. This would imply 
that PKA is ultimately fully active, even at basal and unstimulated state.1 Thus, the major 
working hypothesis for this study was that local PDE4D3 activity shapes a pool of low cAMP 
concentrations at the cardiac RyR to protect the channel from excessive phosphorylation. In 
healthy hearts, β-adrenergic stimulation causes an increase in cAMP, strong enough to 
overcome the PDE4D3 barrier, to activate PKA for channel phosphorylation and Ca2+ gating 
to facilitate myocyte contraction. Quite similar, pathological remodeling causes PDE4D3 
depletion, hyperphosphorylation and leaky RyRs (increased Ca2+ gating during diastole), 
which are associated with heart failure and arrhythmias. 
In consequence, application of rolipram to selectively block PDE4 activity should mimic 
“depletion of PDE4D3” to cause cAMP diffusion into the RyR2 associated microdomain, 
where the Epac1-camps-JNC is supposed to reside and evoke a FRET signal. However, 
significant FRET responses upon rolipram were not detected (see Fig 14A). Analysis of basal 
cAMP hydrolysis revealed a major contribution of PDE3 to total cAMP hydrolysis, and to a 
very small extent PDE4 was also involved (at least detected with the Epac1-camps). Non-
selective PDE inhibition with IBMX caused strong FRET signals in myocytes from Epac1-
camps as well as Epac1-camps-JNC mice, indicating high basal cAMP levels, which had 
amounted to ~1 µmol/L previously.191 The raise in cAMP upon IBMX significantly exceeded 
the effects of single inhibition of PDE3 and PDE4, thus one might propose that these PDEs 
from a “double layer” which controls cAMP levels and one PDE can replace the other (see 
Fig. 14).234 Nevertheless, the Ca2+ leak hypothesis implies that chronic catecholaminergic 
overload causes hyperphosphorylation of the RyR2. Therefore, inhibition of PDEs was 




PDE4 is the major regulator of cAMP amount after beta adrenergic stimulation and a smaller 
contribution of PDE3, as described by others.142, 188, 235 Since inhibition of PDE4 caused 
increases in cAMP levels which were close to the sensor saturation, PDE4 inhibition was 
repeated after a smaller amount of ISO (5 nmol/L) to measure in the dynamic range of the 
FRET sensors. Finally, there was no significant difference in PDE4 activity detectable, when 
comparing RyR2 compartment and cytosol, as this was the case after isoproterenol 100 
nmol/L (see Fig. 15).  
4.1.5   Outlook 
In conclusion, there were no differences in cAMP signaling detectable using cytosolic Epac1-
camps and its targeted version Epac1-camps-JNC. The findings argue against a cAMP 
microdomain that is under control of PDE4 hydrolytic activity. A potential explanation is that 
the cAMP indicator, or at least its cAMP binding domain might be excluded from the 
microdomain and reflects changes in the bulk cytosol despite of cAMP dynamics of the so- 
called RyR2 compartment. One has to imagine that the RyR2 is a large protein, and the 
sensor is targeted to junctin molecule which is not associated to the N-terminal domain of the 
RyR2 where PDE4 should reside but is anchored in the SR membrane only in close 
proximity to the RyR2. Thus, it is most likely that the Epac1-camps-JNC is simply orientated 
in an unfavourable angle to the receptor and localized too far away from the microdomain 
formed by PDE4 activity. One could think of fusing Epac1-camps to another protein of the 
















4.2 Real time visualization of cGMP dynamics in adult 
cardiomyocytes using red cGES-DE5 transgenic mice 
4.2.1   Generation and characterization of red cGES-DE5 transgenic mice 
A new transgenic mouse model with cardiomyocyte-specific expression of the FRET-based 
cGMP biosensor red cGES-DE5198 was generated to allow real time visualization of cGMP 
dynamics in adult cardiomyocytes.208 Transgenic expression of the cGMP indicator did not 
influence morphology of cardiomyocytes and whole hearts, as demonstrated by histological 
and morphometric analysis (see Fig. 16). Neither was any impact on in vivo heart 
performance detectable using transthoracic echocardiography (see Table 4). The fact that 
the transgenic mice have healthy hearts provides the potential to combine the biosensor 
mouse model with various genetic and experimental models of cardiovascular disease to 
monitor cGMP under normal and modified conditions. Red cGES-DE5 mice were crossbred 
with β3-AR-TG or β3-AR-KO mice to generate double transgenic mice, which showed sensor 
expression and overexpression of the β3-AR (red cGES-DE5
+/0; β3-AR
+/0), or sensor 
expression and β3-AR deficiency (red cGES-DE5
+/0; β3-AR
-/-), to study β3-AR-mediated cGMP 
signaling (see Fig. 22).158 Finally transverse aortic constriction surgery was performed on red 
cGES-DE5 mice, to monitor signaling of cGMP in an experimental model of cardiac 
hypertrophy (see Fig. 26).236, 237 As demonstrated by the double transgenic and TAC 
operated mice, the red cGES-DE5 transgenic mice can serve as a basis for further 
investigations, which might help identify new targets for the treatment of heart failure and 
other cardiovascular diseases.  
An alternative to the transgenic mouse is adenovirus-mediated sensor expression in isolated 
cardiomyocytes.206, 210 This technique is not dependent on the time-consuming generation of 
a new transgenic animal model, but has serious disadvantages compared with the sensor 
mice. Single cardiomyocytes are isolated from wildtype mice, infected with red cGES-DE5 
encoding adenovirus and imaging experiments are performed after 48 hours of cell culture, 
which is required for biosensor expression. Culture of isolated cardiomyocytes leads to a 
decrease in cell quality and drastic changes in morphological structures238 that are relevant in 
the regulation of compartmentalized signaling of cyclic nucleotides.233 However, isolation and 
culture of cardiomyocytes have been challenging, especially of adult mouse myocytes.206 
The red cGES-DE5 mice provide the possibility to perform imaging experiments in freshly 
isolated cardiomyocytes showing high levels of cell quality, which is strongly necessary for 




simpler to handle neonatal and adult rat cardiomyocytes, which can be infected with 
adenovirus and kept in culture showing high cell quality (see Fig. 29).   
Measurements of cGMP dynamics are highly demanding and little is known about the spatio-
temporal organization of cGMP in cardiomyocytes, which is mainly due to limitations of 
imaging techniques. There were reports on cGMP measurements in neonatal rat 
cardiomyocytes using FRET-based live cell imaging.35, 141, 148 It is worth mentioning that 
neonatal cardiomyocytes have strongly elevated cGMP levels compared to adult cells, and 
important morphological structures involved in cyclic nucleotide-mediated signaling, are 
absent (such as T-tubules)239, 240 or not fully developed.241 Therefore, neonatal 
cardiomyocytes might not properly reflect cGMP signaling in adult cells. Even more 
important, measurements of real time dynamics of cGMP in cultured rat adult 
cardiomyocytes have been performed using rat olfactory cyclic nucleotide gated (CNG) 
channels as reporters for cGMP.49, 201 Since CNG channels are located at the plasma 
membrane, cGMP detection is limited to the subsarcolemmal compartment and recordings 
do not reflect overal changes in cGMP. Another drawback is very poor selectivity for cGMP 
over cAMP.242 Recently, other cGMP-FRET mouse models were published, with ubiquitous 
and smooth muscle-specific expression of cGi500 probe.220 These mice allow in vivo FRET 
measurements of cGMP in vascular, colon and bladder smooth muscle cells, while 
measurement in the heart were not reported. Due to its lower cGMP affinity (see Table 2), 
cGi500 can detect cGMP levels from approximately 100 nmol/L to 3 µmol/L,180, 220 while 
cGMP levels in adult cardiomyocytes may be below the dynamic range of this sensor.191  To 
my knowledge, red cGES-DE5 transgenic mice allowed the first FRET-based measurements 
of cGMP in adult mouse cardiomyocytes. 
4.2.2   Analysis of cGMP synthesis  
First, cGMP production was induced by treating cardiomyocytes with natriuretic peptides and 
NO donors to activate particulate (GC-A, GC-B) and soluble (NO-GC) guanylyl cyclases. 
Stimulation of GC-B with CNP resulted in strong increases in cytosolic cGMP, while the    
GC-A ligands ANP and BNP evoked only border line responses and SNAP failed to generate 
NO-GC-mediated cGMP (see Fig. 18). Similar results were obtained using RIA-based 
measurements of cGMP stimulations in wildtype cardiomyocytes, which confirms the FRET 
imaging of cGMP, but also suggests that the FRET-based cGMP reporter describes total 
changes in cGMP amount, that most likely occur in the entire cytosol.  
One might conclude that stimulation of GC-B with CNP generates cGMP that can diffuse 




was associated with phosphorylation of phospholamban (PLB), a target of cGMP dependent 
kinase type I (cGKI) in a model of isolated working mouse hearts (see Fig. 20). Various 
studies have showed that CNP causes a robust increase in cGMP levels and cGKI-mediated 
phosphorylation of PLB29, 115, 165, 243, 244 that influences heart function. Most authors described 
posititve lusitropic effects of CNP, while negative29, 243-245 and positive115, 246, 247 influence on 
contractility have been reported. Interestingly, CNP stimulations in working heart 
preparations induced stronger increases in cGMP amount compared with single 
cardiomyocytes (see Fig. 20A, 18F), most likely due to GC-B activity in cardiac fibroblast,248 
which were excluded in the single myocyte measurements. Yet, phosphorylation of PLB gave 
proof that the raise in cGMP was also mediated by GC-B activity in cardiomyocytes of 
working hearts, since fibroblasts lack the PLB protein (see Fig. 20B).  
Even more important is the fact, that RIA-based measurements of cGMP stimulations in 
transgenic mice are required to directly compare cyclase activity in transgenic versus wiltype 
cells. Anyway, measurements of cGMP in FVB/NRj mice proved difficult to perform due to 
low cGMP levels and several attempts to detect cGMP amounts failed. A limited number of 
experiments performed by Birgit Gassner (AG Kuhn, Department of Physiology, Würzburg) 
revealed slightly stronger CNP-stimulated cGMP content in transgenic versus wildtype 
cardiomyocytes which was not statistically significant (352 ± 49 versus 586 ± 92 
fmol/1x105cells, n= 3-4 hearts), therefore further experiments are needed. Due to the fact 
that several attempts to detect cGMP by RIA failed and C57/Bl6 mice show stronger 
increases in cGMP detected with RIA (Michaela Kuhn, personal communication), crossing 
red cGES-DE5 mice into C57/Bl6 background for further investigations was initiated. It is 
worth mentioning that potent CNP-evoked cGMP signals were observed in neonatal and 
adult rat cardiomyocytes infected with red cGES-DE5 sensor (see Fig. 29) further indicating 
a pronounced role of GC-B in cGMP production in rodent cardiac myocytes.  
In contrast to strong cytosolic CNP-mediated cGMP, stimulation of GC-A with ANP and BNP 
evoked only minor effects. However, an absent effect of ANP, as the FRET and RIA 
measurements might suggest, is not postulated. One has to refer to the possibility that ANP-
evoked cGMP pools might be localized close to the plasma membrane and do not reach the 
deeper parts of the cytosol.35, 49, 141 This might also explain the very small effects of GC-A 
stimulation detected in C57/Bl6 mice,29 and in isolated rat cardiomyocytes244 (in both studies 
ANP << CNP), with no influence on contractility.29 In addition, one could observe small 
effects on cAMP levels mediated by PDE3 inhibition after β-adrenergic stimulation, detected 
in Epac1-camps transgenic mice (see Fig. 27). Given the fact that cGMP signaling is 
compartmentalized,49, 141, 148 and PDEs are crucially involved in the regulation of cAMP and 




by its degradation via PDEs. Still, subsequent PDE inhibition failed to unmask ANP-
generated cGMP. Hence, one might suggest that other mechanisms, such as physical 
barriers251 could be involved in the organization of cGMP compartments. A localized version 
of the red cGES-DE biosensor, targeted to the plasma membrane compartment might help 
resolve this issue. Finally, small responses to ANP were detected in neonatal rat 
cardiomyocytes (see Fig. 29), as described in the literature.141  
The lack in FRET signals after treatment with SNAP was unexpected, since numerous 
studies found effects on cardiac functionality, although with contradictory outcomes.68 There 
are several aspects that might help explain the divergent results. First NO acts through 
various pathways, it stimulates NO-CG and thus activates the cGMP/cGKI signaling, but also 
direct effects of NO on proteins via oxidative modification of thiol groups, termed S-
nitrosylation, have been described;252 those are independent of NO-GC and cGMP. Second 
myoglobin acts as a scavenger of NO and prevents NO to reach the target receptor.25, 253 
Anyway, red cGES-DE5 mice were created to monitor cGMP levels and not heart function. It 
is established that NO donors increase cGMP amount in the heart, including vascular smooth 
muscle cells, where classical NO/cGMP signaling occurs. In contrast, cGMP formation in 
cardiomyocytes remains less clear, with studies showing NO-donor-mediated increase in 
cGMP,49, 69 as well as no effects on cGMP content.254  
SNAP is well-established and is the most widely used NO donor, but it might act to slow for 
live cell imaging experiments since the half-life of SNAP is approximately 6 hours at 37°C.255 
Thus, other agents that spontaneously release NO (no prodrugs) were applied, such as 
sodium nitroprusside (SNP) 50 µmol/L, Diethylamine NONOate (DEA/NO) 1 µmol/L and 
PROLI-NONOate (PROLI-NO) 1 µmol/L, which have a different pharmacokinetic profile. For 
instance, DEA/NO and PROLI-NO release NO rapidly in a pH dependent manner, following 
first order process with a half-life of 2 min or 1.8 seconds at 37°C, respectively.256-258 SNP 
agent was prepared freshly before added to the cells, where it releases NO when the drug 
gets in contact with the cell membrane, independently of enzymes. However this class of 
compounds that activate NO-GC via release of NO failed to evoke cGMP signals (see Fig. 
19). Hence, stimulation of β3-adrenergic receptors was tested to induce NO-GC activity, with 
ISO 100 nmol/L in the presence of selective β1-and β2-blockers.
35 Neither in wildtype, nor β3-
AR-overexpressing mice (red cGES-DE5+/0; β3-AR), robust increases of cGMP amount were 
detectable. Also, the NO-GC activator BAY 58-2667 (Cinaciguat), which activates even 
insensitive NO-GC,91 failed to evoke signals.  
As demonstrated, various drugs did not stimulate cGMP production via NO-GC in single 




generation of ROS in the cardiomyocyte, which can oxidize NO-GC and cause insensitive 
enzyme. To exclude this possibility, cardiomyocyte isolation and imaging experiments were 
performed in the presence of the ROS scavenger melatonin,222 which did not lead to 
measurable NO-donor effects.  
Small increases of cGMP upon NO donor treatment have been reported in neonatal rat 
cardiomyocytes, as detected with FRET-based cGMP probes.141, 148 Therefore, neonatal rat 
cardiomyocytes were transiently transfected with red cGES-DE5 biosensor to test, whether 
the cGMP indicator is able to detect cGMP pools that are associated with NO-GC activity or if 
the sensor might be excluded from the NO-GC compartment. Indeed, clear increases in 
cGMP upon stimulation with SNAP were observed (see Fig. 29), as described with the other 
FRET-based cGMP reporters. A possible explanation for SNAP signals detectable in 
neonatal, but absent in adult cells might be a ~3-fold higher expression of NO-GC in neonatal 
versus adult cardiomyocytes.    
As for the neonatal cells, a small increase in cGMP amount was observed in left ventricular 
heart tissue that has been perfused with SNAP in a working heart preparation. The effect 
was rather small compared with the rise in cGMP generated by CNP (~3-fold versus ~12-fold 
increase in cGMP contents) and did not cause cGKI-mediated PLB phosphorylation (see Fig. 
20). This raise in cGMP is most likely due to stimulation of NO-GC in smooth muscle cells, 
which showed strong increases in cGMP production upon application of NO-donors.220 
However, SNAP effect was absent in isolated cardiomyocytes also using RIA-based cGMP 
detection technique (see Fig. 18F). Last, the absence of PLB phosphorylation, which is 
expressed in myocytes but not in smooth muscle cells, supports the hypothesis that 
increases in cGMP content upon SNAP, observed in heart tissue, were generated via the 
classical NO/NO-GC/cGMP-pathway in non-myocyte cells.  
Finally in the presence of β-adrenergic stimulation and concomitant PDE5 inhibition with 
Tadalafil 100 nM, borderline responses upon stimulation were detected in isolated 
cardiomyocytes carrying red cGES-DE5 (3.7 ± 0.4 %, mean± SE, n=12 cells from 3 mice, 
data acquired by Dr. Nikolaev). 
Studies on cGMP generation were mostly performed in heart tissue and not in 
cardiomyocyte-enriched preparations and focused either on NO- or natriuretic peptide-
mediated cGMP formation. Here, both pathways were assessed side by side and GC-B was 
found to be the most active guanylyl cylclase in cardiomyocytes. The role of GC-B in 
cardiomyocytes is poorly understood and probably underestimated, since GC-A and NO-GC 




predominant source of cGMP production in cardiomyocytes, while GC-A and NO-GC play 
much less prominent roles. 
4.2.3   Analysis of basal cGMP formation 
Stimulation of NO-GC did not evoke robust FRET signals, but ODQ revealed basal cGMP 
synthesis via NO-GC, with unstimulated cardiomyocyte cGMP levels amounted to             
~10 nmol/L. Inhibition of GC-A with A71915 failed to decrease resting cGMP levels, 
supporting the fact that unstimulated cGMP levels are produced by NO-GC (see Fig. 21). 
Increased ODQ effects were observed in mice overexpressing the β3-AR, while decreased 
ODQ responses were detected in β3-AR-deficient mice (see Fig. 22). These findings indicate 
that cardiomyocytes from β3-AR-TG mice showed increased basal cGMP, while the β3-AR-
KOs have decreased cGMP, thus supporting a role of the β3-AR in the regulation of basal 
cGMP. However, direct pharmacological stimulation of the β3-AR failed to increase 
cardiomyocyte cGMP. In conclusion, one could postulate that the β3-adrenceptor acts as a 
constitutively active receptor, which maintains basal cGMP levels in myocytes of the adult 
mouse.158 Given the fact that adult cardiomyocytes express little NO-GC (see Fig. 29) and 
basal cGMP synthesis is under control of  β3-adrenoceptors, one might speculate that the 
NO-GC/cGMP system is even at unstimulated state producing cGMP at its maximal capacity, 
which might explain the lack in NO-donor effect. To test this hypothesis, cardiomyocytes 
were incubated in N-Nitro-L-arginine methyl ester (L-NAME) 300 µmol/L, which is an inhibitor 
of NOS, to relieve NO-GC from basal cGMP production and uncouple the cyclase from the 
β3-AR. Hence, endogenous NO-GC stimulation should be decreased to permit a prospective 
NO-donor effect. Still, there were no responses to NO donor after preincubation with L-
NAME observed, suggesting that β3-AR is not the only mechanism that controls basal cGMP 
levels.  
4.2.4   Analysis of cGMP degradation by PDE hydrolytic activity 
FRET measurements of cGMP hydrolysis revealed a strong contribution of PDE3 to total 
cGMP turnover at basal and prestimulated state, while inhibition of PDE1, 2 and 5 activity 
showed only negligible effects (see Fig. 23, 24). PDE3 dominated cGMP degradation in adult 
cardiomyocytes at resting state and after prestimulation with cGMP agonists. However, the 
presence of the competitive substrate cAMP strongly reduced cilostamide-induced FRET 
responses. Nevertheless, PDE3 effects were still stronger than those of the other PDEs, and 
PDE3 remained the major cGMP-PDE. This was also true for a model of heart failure using 




The signals evoked by all PDE blockers were small compared to CNP-induced effects, and 
no clear opposing effects in raw donor (T-Sapphire) and acceptor (Dimer2) single intensities 
could be observed online. Since T-Sapphire intensity (GFP) is vastly higher than Dimer2 
(RFP) and the bleedthrough coefficient was 94 %, it is most likely that small changes in RFP 
intensity channel are simply overlapped by contrary changes in brighter GFP intensity which 
are also detected in the RFP intensity channel but must be substracted afterwards. After 
bleedthrough correction, the single channel intensities showed opposing effects. The 
mismatch in RFP and GFP intensity (GFP>>RFP) is most likely the reason why uncorrected 
donor and acceptor traces did not run into opposite directions after small or modest 
increases in cGMP content, as those seen after CNP application (see Fig. 17). In addition, a 
modified version of Epac1-camps, where CFP and YFP fluorescent proteins were replaced 
by GFP (T-Sapphire) and RFP (Dimer2), respectively, (kindly provided by Prof. Feil, 
Department of Biochemistry, Tübingen) showed similar behavior. Stimulation with ISO to 
induce a strong increase in cAMP showed a change in FRET ratio, but the uncorrected 
single intensity channels ran into the same direction. The original Epac1-camps containing 
CFP/YFP FRET pair showed opposing changes in YFP and YFP intensities even without 
bleedthrough correction after the same cAMP stimulus. Nevertheless, small increases in 
cAMP also can lead to a lack in opposing CFP and YFP intensities detected with Epac1-
camps.       
The finding that PDE3 is the major cGMP-PDE controlling basal cGMP levels was 
unexpected, since PDE3 is mainly described as a cAMP-PDE in the literature.118, 249 Thus, 
PDE hydrolytic activity was assessed in homogenates of isolated cardiomyocytes using a 
classical PDE assay according to Thompson and Appleman. A strong contribution of PDE2 
and PDE5 was found, while cilostamide-sensitive PDE3 hardly affected total cGMP 
degradation (see Fig. 25). These findings do not agree with opposite results detected with 
the FRET approach, but confirm what others have reported.49, 259 Nevertheless, it is important 
to consider that established biochemical assays are carried out at 1 µmol/L cGMP as a 
substrate, while physiological cGMP levels in adult cardiomyocytes are far below this 
concentration, in the low nanomolar range. Those non-physiologically high cGMP levels most 
likely modulate PDE hydrolytic activity. For instance, PDE5 and PDE2 activity can be 
activated by binding of cGMP to regulatory GAF domains, leading to an increase in its cGMP 
hydrolytic activity. This might explain the strong effects of tadalafil (PDE5) and BAY (PDE2) 
on cGMP-induced highly active PDE5 and PDE2, which were not detectable at low cGMP 
with the cGMP indicator, but were overestimated in the PDE activity assay. In addition, PDE2 
shows low affinity (Km = 10 µmol/L) for cGMP compared with PDE3 (Km = 0.02 µmol/L), but a 




µmol/min/mg for PDE3),118 which may also lead to strong response at high cGMP levels. 
Finally, the experiments were performed in lysates in the presence of detergent, which 
causes redistribution of PDEs from their original compartments. Thus, PDEs that normally 
reside in a compartment with higher or lower cGMP levels compared to the bulk cytosol, are 
now homogenously distributed and hydrolyze total cGMP. Therefore, FRET measurements 
of cGMP dynamics in living intact cardiomyocytes at endogenous cGMP levels might better 
reflect PDE hydrolytic activities than classical biochemical PDE activity assays.         
4.2.5 Analysis of cGMP dynamics in a model of moderate pressure-
overload induced hypertrophy  
Transverse aortic constriction surgery was performed to induce hypertrophy and associated 
ventricular remodeling. PDE3 remained the major regulator of cGMP turnover and CNP 
effects were unchanged. Increased effects of the PDE5 inhibitor tadalafil were present in 
diseased cardiomyocytes, but not in control cells (see Fig. 26). It has been shown that PDE3 
expression and activity was downregulated, while PDE1 was upregulated in mouse models 
of chronic pressure-overload using aortic banding.138, 144 In those studies, TAC resulted in 
heart failure with depressed systolic performance, whereas imaging experiments of PDE3 
hydrolytic activity were performed in a mild model of completely compensated hypertrophy, 
which most likely failed to depress PDE3 and induce PDE1 expression. Nevertheless, 
increased PDE5 hydrolytic activity as previously described by others.30, 167, 260 could be 
recorded. Finally, responses to CNP were unaltered, which confirms a recent study that 
revealed unchanged strong GC-B-mediated cGMP production, in a mouse model of heart 
failure using aortic banding, while signaling of GC-A was significantly depressed. The 
authors claimed that CG-B was the major natriuretic peptide receptor in the failing heart. 261      
4.2.6   Analysis of cGMP/cAMP crosstalk in adult mouse cardiomyocytes 
The interplay between the cGMP and cAMP signaling pathways was visualized using Epac1-
camps mice, with a main focus on the role of PDE3. It is well known that cGMP can block 
PDE3 hydrolysis,118 and act as a cAMP-PDE inhibitor. When the effects of cGMP on            
β-adrenergic receptor-evoked cAMP signals were investigated, natriuretic peptides 
potentiated β-AR-induced cAMP by cGMP-mediated inhibition of PDE3. Activation of GC-B 
by CNP showed significantly stronger effects than the stimulation of GC-A by ANP. These 
findings are in line with measurements of cGMP in red cGES-DE5 mice, where CNP induced 
the strongest increases in cGMP and ANP smaller responses. Furthermore, stimulation of 




cyclic nucleotide signaling systems. However, SNAP induced an effect when PDE5 was 
blocked (see Fig. 27).  
It has been demonstrated that cGMP signals induced by GC-B stimulation via CNP do 
interfere with β-AR-generated cAMP signaling, which leads to a positive inotropic effect in 
failing rat cardiomyocytes.234 Inhibition of PDE3 was postulated as the mechanism, 
confirming the observations in Epac1-camps mice and providing a proof that GC-B-induced 
cGMP/cAMP crosstalk is highly relevant, since it can have an impact on myocyte 
contractility. The CNP-induced positive effect on contractilie force was only detectable in the 
presence of catecholamines, which supports the finding that CNP applied alone could not 
raise cAMP levels. Furthermore, stimulation of isolated work performing hearts or ventricular 
muscle strips with CNP showed a biphasic response with an initial increase in inotropy 
followed by a negative effect.29, 243 The early positive inotropic effect might be explained by 
cGMP-mediated inhibition of PDE3, while the subsequent decrease in contraction force is 
due to cGMP-induced activation of cGKI activity, which blunts excitatory effects of 
catecholamines.243 In addition, PDE2 hydrolytic activity was blocked, since its cAMP-
hydrolytic activity can be activated by cGMP,227 which might reduce CNP-mediated effects. 
However, inhibition of PDE2 could not generate a rise in CNP-induced cAMP concentrations, 
which was also true for inhibition of PDE5 by tadalafil. Those findings in cAMP sensor mice 
support the hypothesis that PDE3 dominates cytosolic GC-B-mediated cAMP/cGMP 
crosstalk after stimulation of β-adrenoceptors, while PDE2 and PDE 5 seem not to be 
involved.  
ANP-induced increases in cAMP constituted less than 25 % of the maximal increase in 
cAMP that can be attained by total inbibition of PDE3 with cilostamide. Measurements of 
myocyte contractility showed no influence of ANP,116, 262 which might go in line with the 
modest increase in cAMP. Nevertheless, a targeted cAMP biosensor, which resides mainly in 
the particulate fraction of myocyte lysates could reveal a dominant role of ANP in 
cAMP/cGMP interplay mediated via PDE2 hydrolytic activity in neonatal rat cardiomyocytes.  
The authors reported that those effects were not detectable with a biosensor, located in the 
soluble fraction of neonatal rat cardiomyocytes.141 Since global cAMP levels were visualized, 
one has to consider that the Epac1-camps cannot resolve these local changes in cAMP. It 
would be interesting to see whether a targeted version of Epac1-camps sensor, probably 
targeted to the plasma membrane, might detect these local effects.   
SNAP per se could not increase cAMP levels, but pretreatment with the PDE5 inhibitor 
tadalafil could reveal small responses. This is in agreement with measurements of cGMP 




the presence of ISO and tadalafil small responses were detected. Furthermore, it has been 
demonstrated that NO-GC-mediated cGMP pools are under tight regulation of PDE5 in 
connection with β-adrenergic stimulation.49, 148, 262 
4.2.7   Outlook 
The red cGES-DE5 transgenic mouse line harbors great promise for future investigations. As 
demonstrated with aortic banding experiments and for the β3-AR, one can combine the 
mouse model with further genetic and experimental models of cardiovascular disease. In 
particular, myocardial infarction surgery to induce harsher stimuli on myocyte remodeling 
would greatly supplement the observations in the mild model of compensated hypertrophy. 
For the analysis of cGMP microdomains, it is necessary to generate targeted versions of red 
cGES-DE5, for instance targeted to the plasma membrane or PLB. Such targeted sensors  
have already been created and the mouse lines are under investigation. Here, it might be 
possible to detect robust ANP and NO-donor effects. In addition, the red cGES-DE5 mouse 
line was crossed into C57/Bl6 background, which generally shows higher increases in cGMP 
amounts upon stimulation, compared with the FVB/NjR mice. In addition, it is possible to 
combine FRET-based cGMP imaging with the scanning ion conductance microscopy (SICM) 
technique to further dissect the localization of various receptors. Nonetheless, an important 
limitation of the live cell imaging approach is the fact that cGMP signaling in single isolated 
cardiomyocytes might differ from cGMP dynamics under in vivo conditions. It is worth 
mentioning that red cGES-DE5 expression occurs exclusively in cardiomyocytes, and one 
could perform cGMP imaging of an entire heart. To do so, a living heart can be quickly 
removed and perfused in analogy to the working heart experiments (see 2.2.6) for imaging 
experiments performed under a binocular microscope using low magnification. Finally, it is 
possible to generate double-transgenic mice that express Epac1-camps and red cGES-DE5 
to measure cAMP and cGMP dynamics simultaneously. Such an experiment can be 
performed at 405 nm excitation of CFP and GFP combined with four colour imaging of CFP, 
YFP, GFP, and RFP emissions.198 Such double-transgenic mice have already been created 
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